Neurostimulation Devices Market (2nd Edition), 2018-2030

Neurostimulation Devices Market (2nd Edition), 2018-2030

The National Academy of Medicine indicates that as many as 100 million people in the US suffer from some form of pain, which has been shown to be associated with a socioeconomic burden of around USD 600 billion per year, in treatment costs and lost productivity. , Further, it has been estimated that nearly 1 million people in America suffer from Parkinson’s disease, with approximately 60,000 new patients being diagnosed every year. Over the past few decades, the prevalence of such chronic disorders has grown at an alarming rate. In fact, a recent World Health Organization’s Global Burden of Disease study recognized these chronic conditions as one of the leading causes of deteriorating public health in the world. Such clinical conditions have often been shown to result in serious physical, cognitive and psychosocial consequences in patients. This indicates an urgent need for novel and effective treatment methods as the drawbacks of existing treatment options (such as high risk of addiction / abuse associated with long-term use of oral opioids, and complications due to complex surgical procedures) are substantial.

Extensive research in the field of neurostimulation has demonstrated the potential of this technique in providing therapeutic relief to a number of patients, who have developed resistance to conventional medication. Since the introduction of the first neurostimulation therapy in 1960s, their numerous observed benefits, such as reversible and minimally invasive nature of the procedures (to administer such treatments), targeted approach to therapeutic relief that can be modulated as well, provisions for integrating various safety mechanisms, and negligible use of opioids / other medications, have captured the interest of several stakeholders in the industry. In fact, since 2010, over 4,000 patents have been published in this domain, indicating the rapid pace at which research is being carried out. It is anticipated that such efforts are likely to boost the overall growth of this market in the coming years.

SCOPE OF THE REPORT
The ‘Neurostimulation Devices Market (2nd Edition), 2018-2030’ report features an extensive study of the current landscape and future outlook of the growing market for neurostimulation devices. The focus of this study is on invasive neurostimulation devices, such as devices for spinal cord stimulation (SCS), deep brain stimulation (DBS), spinal nerve stimulation (SNS), vagus nerve stimulation (VNS), other cranial nerve stimulation (Other CNS) and other variants of neurostimulation devices. Amongst other elements, the report features:

A detailed assessment of the overall landscape of neurostimulation devices market, featuring the contributions of various companies engaged in this domain and highlighting key device specifications (size, weight, battery type, battery life, number of electrodes, type of programming, and MRI compatibility), along with information on different types of neurostimulation devices, target therapeutic areas, and regulatory approvals received across various geographies.

A comprehensive product competitiveness analysis, taking into consideration the supplier power and specific device-related parameters, such as number of target indications, target nerves, regulatory approvals, and key device specifications.

Comprehensive profiles of developers of leading neurostimulation devices (shortlisted on the basis of the product competitiveness analysis), featuring an overview of the company, its financial information (if available), and a detailed description of the device(s). Each profile also includes a list of recent developments, highlighting the achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the foreseen future.

An elaborate discussion on the regulatory landscape related to medical devices across various geographies, namely North America (the US and Canada), Europe (the UK, Germany, France, Spain and Italy), and Asia-Pacific (Australia, China and Japan). The information covers details on the payer mix, and the reimbursement processes of various public / private organizations across these geographies.

A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of product portfolio), highlighting the current perceptions regarding their proprietary brands across different device types, taking into consideration several aspects, such as strength / diversity of product portfolio, extent of patent portfolio, recent collaborations, number of target indications and regulatory approvals, and the overall market positioning of the players.

An in-depth analysis of the patents that have been published since 2013. The analysis also highlights the key trends associated with these patents, including patent type, regional applicability, CPC classification, IP litigations, emerging areas, leading industry players (in terms of number of patents filed / granted), and patent benchmarking and valuation.

A comprehensive clinical trial analysis of completed, ongoing and planned studies of various neurostimulation devices. For the purpose of this analysis, we looked at the clinical studies that have been last updated in 2013, and analyzed them on the basis of various parameters, such as current trial status, regional distribution, leading industry and non-industry players, key indications, and enrolled patient population across different geographies.

An analysis of the partnerships that have been established in the recent past, covering product development / commercialization agreements, R&D collaborations, technology licensing deals, distribution agreements, mergers / acquisitions, and others.

An analysis of investments made at various stages of product development / commercialization; these include seed financing, venture capital financing, debt financing and grants / awards received by the companies that are operating in this domain.

A comprehensive list of non-invasive neurostimulation devices, along with information on their developers, various types of non-invasive technologies used, target therapeutic areas, and development / approval status of the devices.

An elaborate discussion on the upcoming opportunities / trends in the field of neurostimulation devices that are likely to impact the evolution of this market over the coming years.

One of the key objectives of the report was to estimate the existing market size and potential growth opportunities for neurostimulation devices. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market over the period 2018-2030. The report provides sales forecasts for the overall neurostimulation devices market with detailed market segmentation on the basis of type neurostimulation devices (SCS, DBS, VNS, and other types), indication (chronic pain, dystonia, epilepsy, essential tremor, heart failure, major depressive disorder, Parkinson’s disease, obsessive compulsive disorder, overactive bladder, sleep apnea), MRI compatibility (MRI compatible and MRI non-compatible), and the geographical distribution of the market (US, Canada, UK, Germany, France, Spain, Italy, Australia, China, and Japan). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry’s evolution.

The opinions and insights presented in this study were also influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
Dave Rosa (President and Chief Executive Officer, NeuroOne Medical Technologies)
Deborah Schmalz (Vice President, Regulatory Affairs, Clinical Research and Compliance, ReShape Lifesciences) and Diane Utzman-O’Neill (Vice President, Marketing, ReShape Lifesciences)
Jan Pieter Heemels (Vice President, Commercial Operations, Mainstay Medical)
Laura Tyler Perryman (Chief Executive Officer, Stimwave)
Luca Ravagnan (Chief Executive Officer, WISE)
Steve Goedeke (President and Chief Executive Officer, Cardionomic)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. Over 120 implantable neurostimulation devices are presently available / under development for the treatment of chronic disorders. Of these, close to 31% are spinal cord stimulating (SCS) products indicated for managing different forms of chronic pain. Examples include (in alphabetical order, no specific selection criteria) Algovita®, Altius® System, Intellis™, Precision Spectra™, Proclaim™ Elite, Senza®, and StimRouter®. These are followed by deep brain stimulation (DBS) devices (20%) that are designed to stimulate globus pallidus / subthalamic nucleus, ventral intermediate of the thalamus and other portions of the brain for the treatment of neurological / movement-related disorders. Other therapeutic areas for which such devices are available / under evaluation include urological disorders, respiratory disorders, cardiovascular disorders, gastrointestinal disorders, sleep disorders and metabolic disorders.

2. Around 75% of the companies that are involved in the development of neurostimulation devices are small-sized firms / start-ups (less than 200 employees). Examples of such players include (in alphabetical order, no specific selection criteria) Cardionomic, Lungpacer Medical, Neuros Medical, Nyxoah, Respicardia, SPR Therapeutics and Stimwave. However, the overall market is currently dominated by a few well-established players that are actively developing / improving their proprietary technologies in order to further increase their footprint in this competitive domain. Examples of such players include (in alphabetical order, no specific selection criteria) Abbott (St. Jude Medical), Boston Scientific, LivaNova, Medtronic and Nevro.

3. It is worth highlighting that more than 45% approvals have been granted to various neurostimulation devices in the EU, followed by approvals granted by the US FDA, Australian TGA and Health Canada for the treatment of different chronic clinical conditions. In fact, close to 65 marketing approvals have been granted to these devices across different regions since 2015. Examples of devices approved in the year 2018 include (in alphabetical order, no specific selection criteria) Axonics® r-SNM™ System (TGA approval for overactive bladder), SenTiva® (CE Mark for epilepsy), Senza II™ (CE Mark for chronic pain), Spectra WaveWriter™ (US FDA approval for chronic pain), StimGuard’s SNS system (CE Mark for overactive bladder), StimRouter® (Health Canada approval for chronic peripheral nerve pain), and TransAeris™ System (CE Mark for ventilator-induced diaphragm dysfunction).

4. Close to 45% of the neurostimulation devices feature magnetic resonance (MR) conditional labeling, allowing patients to undergo safe magnetic resonance imaging (MRI) of full body / specific body parts. Further, around 40% of neurostimulation devices utilize rechargeable batteries in their implantable pulse generators (IPGs), while close to 15% of devices have battery-free IPGs in order to deliver minimally invasive therapies to the patients.

5. Extensive research efforts in this domain have resulted in the publication of over 4,000 patents since 2010. Stakeholders that have filed / been granted the maximum number of patents related to neurostimulation devices in the last 8-10 years include (in decreasing order of number of patents) Boston Scientific, Medtronic, LivaNova, Abbott (St. Jude Medical), NeuroPace, and Metavention.

6. Further, close to 1,000 clinical studies have been registered (completed / ongoing / planned) across different geographies. Based on the number of trials, North America (~380 trials) has emerged as a major research / innovation hub in this domain; about 55% of the total number of patients enrolled in the aforementioned trials were reported to have been recruited in centers in this region, followed by Europe and Asia-Pacific. Further, the maximum number (150) of trials evaluating neurostimulation devices were observed to be associated with chronic pain.

7. Capital investments, totaling USD 1.8 billion have been made across over 100 instances in this domain since 2015. Examples of companies that have received relatively more funding include (in reverse chronological order) Inspire Medical Systems (USD 108 million), Metavention (USD 65 million in 2018), NeuroPace (USD 74 million in 2017), ReShape Lifesciences (USD 61 million in 2017), and CVRx (USD 93 million in 2016), and Nevro (USD 173 million in 2016). Examples of prominent venture capital investors that have actively purchased equity in this domain include (in decreasing order of the number of instances) Action Potential Venture Capital, Atlante Ventures, Gilde Healthcare Partners, Cormorant Asset Management, Andera Partners, F3F, and KCK Group.

8. The market for neurostimulation devices is expected to grow at an annualized rate of 10.9% between 2018 and 2030. While SCS devices, intended primarily for pain management, are expected to occupy majority of the share (close to 57%) in the market, DBS devices (utilized for the treatment of neuropsychological disorders) are anticipated to grow at a relatively faster rate (14.8%) in the forecast period. Further, the major share (over 75%) of revenues is anticipated to be distributed between North America and Europe; however, we believe that certain Asian countries, such as China, are likely to grow at a faster rate as compared to other regions over the coming decade; this is attributed to the increasing awareness about the nature of these therapies and a less stringent regulatory environment.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the neurostimulation devices market in the mid to long term.

Chapter 3 is an introductory chapter that presents a general overview of the epidemiology and the growing prevalence of chronic clinical conditions, along with information on the limitations of conventional treatment methods. Further, it features a detailed discussion on neurostimulation devices, including a comprehensive history of development, information on their basic components and principle of operation, and associated advantages / challenges. It also features a discussion on the key types of neurostimulation devices, including SCS, DBS, SNS, VNS, Other CNS, and other device types, featuring information on the potential applicability of these devices across different disease indications. Further, the chapter features a discussion on the key growth drivers and road blocks related to neurostimulation and its use in treating various neurological conditions.

Chapter 4 provides a detailed description on the regulatory landscape related to medical devices across various geographies, namely North America (the US and Canada), Europe (the UK, Germany, France, Spain and Italy), and Asia-Pacific (Australia, China and Japan). Further, it provides information on the payer mix, and details of the reimbursement processes of various public / private organizations across different geographies.

Chapter 5 includes information on more than 125 invasive neurostimulation devices that are either commercialized or under development for the treatment of different disorders. It features detailed analyses of these devices based on key specifications (including size, weight, battery type, battery longevity, number of electrodes, and MRI compatibility), Further, we have provided information on different types of neurostimulation devices, target nerves, target therapeutic areas, and regulatory approvals received across various geographies. The chapter also highlights the contributions of various companies engaged in this domain, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 6 provides a detailed review of SCS devices, along with information on their historical evolution and associated surgical procedures (for implantation). The chapter also presents a comprehensive 2 X 2 matrix to compare device competitiveness, by taking into consideration the supplier power (based on size of employee base) and certain device-related parameters, such as number of target indications, target nerves, regulatory approvals, and key specifications of the devices (including size, weight, battery type, battery longevity, number of electrodes, type of programming, and MRI compatibility). In addition, the chapter includes elaborate profiles of the developers of leading SCS devices (shortlisted on the basis of device competitiveness analysis scores); each profile features an overview of the company, its financial information (if available), detailed description of the device(s) and the recent developments and future outlook with respect to the specific device(s) / overall neurostimulation domain.

Chapter 7 provides a detailed review of DBS devices, along with information on their historical evolution and associated surgical procedures (for implantation). The chapter also presents a comprehensive 2 X 2 matrix to compare device competitiveness, by taking into consideration the supplier power (based on size of employee base) and certain device-related parameters. In addition, the chapter includes elaborate profiles of the developers of leading DBS devices (shortlisted on the basis of device competitiveness analysis scores); each profile features an overview of the company, its financial information (if available), detailed description of the device(s) and the recent developments and future outlook with respect to the specific device(s) / overall neurostimulation domain.

Chapter 8 provides a detailed review of PNS devices (including SNS, VNS and Other CNS devices), along with information on their historical evolution and associated surgical procedures (for implantation). The chapter also presents three comprehensive 2 X 2 matrices to compare device competitiveness within each type of PNS devices, by taking into consideration the supplier power (based on size of employee base) and certain device-related parameters. In addition, the chapter includes elaborate profiles of the developers of leading devices within each type (shortlisted on the basis of respective device competitiveness analysis scores); each profile features an overview of the company, its financial information (if available), detailed description of the device(s) and the recent developments and future outlook with respect to the specific device(s) / overall neurostimulation domain.

Chapter 9 provides an elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of strength of product portfolio) highlighting the current perceptions regarding their proprietary brands across different device types. The analysis takes into consideration several aspects, such as strength / diversity of product portfolio, strength of patent portfolio, recent collaborations, number of target indications and regulatory approvals, and the overall market positioning of the companies.

Chapter 10 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For the purpose of this analysis, we considered those patents that have been published since 2013 related to the neurostimulation domain. The analysis also highlights the key trends associated with these patents, including patent type, regional applicability, CPC classification, IP litigations, emerging areas, leading industry players, and patent benchmarking and valuation.

Chapter 11 provides a comprehensive clinical trial analysis of completed, ongoing and planned studies of various neurostimulation devices. For the purpose of this analysis, we looked at the clinical studies that have been last updated in 2013, and analyzed them on the basis of various parameters, such as current trial status, regional distribution, leading industry and non-industry players, key indications, and enrolled patient population across different geographies.

Chapter 12 features an elaborate discussion and analysis of the various partnerships / collaborations that have been inked amongst players in this market. It includes a brief description on the various types of partnership models (such as product development / commercialization agreements, R&D collaborations, technology licensing deals, distribution agreements, mergers / acquisitions, and others) that have been employed by stakeholders in this domain, and analysis on the trend of partnerships inked since 2015. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to neurostimulation devices. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 13 provides information on the funding instances and investments that have been made in the neurostimulation domain. The chapter includes details on various types of investments (such as seed financing, venture funding, debt financing and grants) received by companies between 2015 and mid-2018, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 14 features a comprehensive market forecast, highlighting the future potential of neurostimulation devices till 2030 based on multiple parameters, such as prices of devices, indication / region specific adoption trends, and competitive landscape. We have segmented the market on the basis of type of neurostimulation devices (SCS, DBS, VNS, and other types), indication (chronic pain, dystonia, epilepsy, essential tremor, heart failure, major depressive disorder, Parkinson’s disease, obsessive compulsive disorder, overactive bladder, and sleep apnea), MRI compatibility (MRI compatible and MRI non-compatible), and the geographical distribution of the market (US, Canada, UK, Germany, France, Spain, Italy, Australia, China, and Japan). We have adopted a bottom up approach, backed by robust data and credible inputs from primary research, to estimate the likely size of the market, both in terms of value (USD billion) and volume (number of devices).

Chapter 15 presents a discussion on the upcoming opportunities / trends in the field of neurostimulation devices that are likely to impact the future evolution of this market over the coming years. These include (but not limited to) development of devices against unexplored therapeutic areas, integration of novel and advanced features, launch in different geographies, increased utilization of real world evidence-based insights, and implementation of cybersecurity measures in the devices.

Chapter 16 is a collection of executive insights of the discussions that were held key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Dave Rosa (President and Chief Executive Officer, NeuroOne Medical Technologies), Deborah Schmalz (Vice President, Regulatory Affairs, Clinical Research and Compliance, ReShape Lifesciences) and Diane Utzman-O’Neill (Vice President, Marketing, ReShape Lifesciences), Jan Pieter Heemels (Vice President, Commercial Operations, Mainstay Medical), Laura Tyler Perryman (Chief Executive Officer, Stimwave), Luca Ravagnan (Chief Executive Officer, WISE), and Steve Goedeke (President and Chief Executive Officer, Cardionomic)

Chapter 17 is an appendix, which provides a comprehensive list of non-invasive neurostimulation devices, along with information on their developers, types of non-invasive neurostimulation technologies, target therapeutic areas, and development / approval status of the devices.

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 19 is an appendix, which provides the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. Abbott
2. Aberdare Ventures
3. Academy Medical Center
4. Accelmed Growth Partners
5. Action Potential Venture Capital
6. AcuKnee
7. AdvaStim
8. Advent Life Sciences
9. Aetion
10. Aetna
11. AG2R La Mondiale
12. Alan Neuromedical Technologies
13. ALC Healthcare
14. Alere
15. Aleva Neurotherapeutics
16. Alfred Mann Foundation
17. Allergan
18. Allianz
19. American Academy of Neurology
20. American Academy of Pain Medicine
21. American Medical Association
22. Amzak Health
23. Andera Partners
24. Anomali
25. Antares Capital
26. Anthem
27. Aperture Venture Partners
28. ARAG Group
29. Atlante Ventures
30. Atrotech
31. Attivo Networks
32. Aucta Technologies
33. Autonomic Technologies
34. Autonomix Medical
35. Avery Biomedical Devices
36. Aviva
37. AXA PPP Healthcare
38. Axilum Robotics
39. Axiobionics
40. Axonic Capital
41. Axonics Modulation Technologies
42. Banexi Ventures
43. Barclays
44. Bayer
45. BB Biotech Ventures
46. BC Platforms
47. Becton Dickinson
48. Beijing PINS Medical
49. Beijing Tiantan Hospital
50. Biegler
51. BioControl Medical
52. BioElectronics
53. Bioinduction
54. BioMedical Life Systems
55. BioMedPartners
56. Bioness
57. BioScience Managers
58. BioWave
59. BioWin
60. BlueWind Medical
61. Boston Scientific
62. Brain State Technologies
63. Brainlab
64. BrainsGate
65. BrainsWay
66. b-to-v Partners
67. Bupa
68. Cala Health
69. Calmare Therapeutics
70. Canadian Agency for Drugs and Technologies in Health
71. Cancer Prevention and Research Institute of Texas
72. Capricorn Venture Partners
73. Carbon Black
74. Cardionomic
75. Carlos III Health Institute
76. Case Western Reserve University
77. Caser Seguros
78. Catholic University of Leuven
79. CBC Banque & Assurance
80. CEFALY Technology
81. Celgene
82. CensorNet
83. Center for Sensorimotor Neural Engineering
84. Centers for Medicare & Medicaid Services
85. Centripetal Networks
86. Centro of Construction of Cardiac Stimulators of Uruguay
87. Cerbomed
88. Cerevast Medical
89. Certara
90. Cervel Neurotech
91. Chattem
92. Cibiem
93. CICA
94. Cigna
95. Clearly Present Foundation
96. Cleveland Clinic
97. Clinakos
98. Clinigen Group
99. Cogentix Medical
100. Coridea
101. Cormorant Asset Management
102. Cosman Medical
103. Covidien
104. Crédit Mutuel Group
105. CrowdStrike
106. CVRx
107. Cylance
108. Darktrace
109. Deep Brain Innovations
110. Defense Advanced Research Projects Agency
111. Deutsche Krankenversicherung
112. DEYMED Diagnostic
113. Dolphin Neurostim
114. Dr. Langer Medical
115. DyAnsys
116. EaglePicher Medical Power
117. EBS Technologies
118. electroCore
119. ElectroMedical Technologies
120. Electronic Waveform Lab
121. Elron Electronic Industries
122. ELvation
123. Endeavour Vision
124. Endonovo Therapeutics
125. EndoStim
126. eNeura
127. Enopace Biomedical
128. Enspire DBS Therapy
129. Epimed International
130. ERGO Group
131. Evergreen Medical Technologies
132. Evidera
133. Exabeam
134. Expatriate Healthcare
135. F3F
136. Federal Holding and Investment Company
137. Finetech Medical
138. FireEye
139. Firstkind
140. Fisher Wallace Laboratories
141. Flashpoint
142. Flatiron Health
143. Flow Neuroscience
144. Fogarty Institute for Innovation
145. Forbion Capital Partners
146. Forrestal Capital
147. Fortinet
148. Fountain Healthcare Partners
149. Freedom Health
150. French National Authority for Health
151. Frontcourt Ventures
152. Functional Neuromodulation
153. FundRx
154. Gala Therapeutics
155. Galvani Bioelectronics
156. Generali Deutschland
157. German Institute of Medical Documentation and Information
158. Gigamon
159. Gilde Healthcare Partners
160. GiMer Medical
161. Gimv
162. GlaxoSmithKline
163. Gradient Medical
164. Greatbatch
165. Green Park & Golf Ventures
166. GTX Medical
167. Hannover Re
168. HBM Healthcare Investments
169. HealthCore
170. Helius Medical Technologies
171. Helpucover
172. HiDow
173. High-Tech Gründerfonds
174. Hollywog
175. Horowitz Group
176. Humana
177. Humanitas Clinical Institute
178. ICON
179. INC Research
180. InCube Labs
181. Indegene
182. IndependiCare
183. Ingress Health
184. Initiative Capital Romandie
185. INKEF Capital
186. Innogest Capital
187. Innovative Health Solutions
188. Inspire Medical Systems
189. Institute for Industrial Science
190. Institute for Quality and Efficiency in Health Care
191. Institute for Hospital Remuneration System
192. Institute of Hospitalization and Care of Scientific Character
193. Institute of Medical Arts
194. InterWest Partners
195. InterX Technologies
196. IntraPace
197. IPF Partners
198. IQVIA
199. iTENS
200. Johari Digital Healthcare
201. Johnson & Johnson
202. JumpStart
203. Kairuku
204. Kaiser Permanente
205. KCK Group
206. Kinled Holding
207. Kleiner Perkins
208. La Luxembourgeoise
209. LABORIE Medical Technologies
210. Legend Capital Management
211. Leonite Capital
212. Lightstone Ventures
213. Linguamatics
214. LivaNova
215. LogRhythm
216. Lone Star Neuromodulation
217. Longitude Capital
218. LSP
219. Lungpacer Medical
220. MAAF Assurances
221. MAG & More
222. Magstim
223. MagVenture
224. Mainstay Medical
225. Massachusetts Life Science Center
226. Mayo Clinic
227. Mayo Foundation for Medical Education and Research
228. McAfee
229. McKesson
230. MDC Partners
231. Meagan Medical
232. Medaffcon
233. Med-Ally
234. Medical University of South Carolina
235. Medicines and Healthcare products Regulatory Agency
236. Medi-Line
237. Medisana
238. MedSec
239. Medtronic
240. MEMStim
241. Mercy
242. Metavention
243. Micro-Leads
244. MicroTransponder
245. Minnetronix
246. Morgenthaler
247. Munich Re
248. MyndTec
249. National Agency for Medicines and Health Products Safety
250. National Engineering Laboratory for Neuromodulation
251. National Institute of Excellence in Health and Social Services
252. National Institute of Health and Clinical Excellence
253. National Institute of Medical Sciences and Nutrition Salvador Zubiran
254. National Institutes of Health
255. National Neuroscience Institute
256. Nature's Gate
257. NeoMed Management
258. NeoSync
259. Nervana Systems
260. Netherlands Enterprise Agency
261. Neuralieve
262. neuroCare
263. Neuroelectrics
264. NeuroEM Therapeutics
265. NeuroHabilitation
266. NeuroMetrix
267. Neuromod
268. Neuronetics
269. NeuroOne Medical Technologies
270. NeuroPace
271. NeuroQore
272. NeuroRecovery Technologies
273. Neuros Medical
274. NeuroSigma
275. NeuroTek Medical
276. Neurova
277. Neurowave Medical Technologies
278. Nevro
279. New Enterprise Associates
280. Newronika
281. Newton Biocapital
282. Nexeon MedSystems
283. Nexstim
284. Nia Therapeutics
285. Niveus Medical
286. Novallia
287. Novartis
288. NTLab
289. Nuvectra
290. Nyxoah
291. Ohio Third Frontier
292. OMRON Healthcare
293. OrbiMed Advisors
294. Oregon Health & Science University
295. Orthofix
296. Osage University Partners
297. Ottobock
298. Oxford Finance
299. Pain Alliance Europe
300. PainPod BioTechnology
301. Palantir
302. Palo Alto Networks
303. Parasym Health
304. PAREXEL
305. PathMaker Neurosystems
306. PerkinElmer
307. Pharmaceuticals and Medical Devices Agency
308. PhysIOL
309. Ping An Insurance
310. PlatoScience
311. Presidio Partners
312. Principia SGR
313. Prizm Medical
314. ProtectWise
315. Rainbow Medical
316. Reeve Foundation
317. Regional investment Company of Wallonia
318. RenalGuard Solutions
319. Renewal Technologies
320. ReShape Lifesciences
321. Respicardia
322. RITM
323. Ritmedic
324. Saama Technologies
325. Saga Health Insurance
326. Saluda Medical
327. Samsung Electronics America
328. Sanderling Ventures
329. Sanitas
330. Santé Ventures
331. Sapiens Steering Brain Stimulation
332. Scion NeuroStim
333. SegurCaixa Adeslas
334. Sensory NeuroStimulation
335. SetPoint Medical
336. Shape Security
337. SHYFT Analytics
338. Siemens
339. Silicon Valley Bank
340. Silk’n Therapy
341. Smiths Medical
342. Sofinnova Partners
343. Sophos
344. Soterix Medical
345. Southern California Permanente Medical Group
346. SPR Therapeutics
347. St. Jude Medical (Abbott)
348. StimGuard
349. StimRelieve
350. Stimwave
351. SUBLIMED
352. SUNMAS
353. Synapse Biomedical
354. Synergia Medical
355. Syntilla Medical
356. Tal Medical
357. Tempus
358. TENS Rx
359. Theranica Bio-Electronics
360. Threat Stack
361. Thync
362. Topspin Partners
363. TraceSecurity
364. Trustwave
365. Tsinghua University
366. TYRX
367. Ultra Care Systems
368. UnitedHealthcare
369. University of Brussels
370. University of California
371. University of Milan
372. University of Minnesota
373. University of New Mexico
374. University of Pittsburgh
375. University of Tokyo
376. University of Washington
377. US Department of Defense
378. US Department of Homeland Security
379. US Venture Partners
380. USCI Japan
381. VA Office of Research and Development
382. Valencia Technologies
383. Valtronic
384. Vectra Networks
385. Vention
386. Venture Bank
387. Versant Ventures
388. Virility Medical
389. Vision Sciences
390. Vital Motion
391. VitalityHealth
392. Wellington Partners
393. Windham Venture Partners
394. Wisconsin Alumni Research Foundation
395. WISE
396. Xavant Technology
397. Yongjin Group
398. Ysios Capital Partners
399. Zenedge
400. Zephyr Health
401. ZOLL Medical
402. ZTE
403. Zynex Medical


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. An Overview of the Nervous System
3.2. Neurological Impairment
3.2.1. Global Burden of Neurological Disorders
3.2.2. Conventional Treatment Methods for Neurological Disorders
3.3. An Overview of Neuromodulation
3.4. Neurostimulation Devices
3.4.1. Historical Development
3.4.2. General Components and Working Principle
3.4.3. Types of Neurostimulation Devices
3.4.3.1. Spinal Cord Stimulation
3.4.3.2. Deep Brain Stimulation
3.4.3.3. Peripheral Nerve Stimulation
3.4.3.3.1. Spinal Nerve Stimulation
3.4.3.3.2. Vagus Nerve Stimulation
3.4.3.3.3. Other Cranial Nerve Stimulation
3.4.3.4. Comparison of Different Types
3.4.4. Advantages and Limitations
3.4.5. Potential Applications
3.4.6. Growth Drivers and Roadblocks
3.5. Social Media Trends Related to Neurostimulation Devices
4. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES
4.1. Chapter Overview
4.2. General Regulatory and Reimbursement Guidelines for Medical Devices
4.3. Regulatory and Reimbursement Landscape in North America
4.3.1. The US Scenario
4.3.1.1. Regulatory Authority
4.3.1.2. Review / Approval Process
4.3.1.3. Reimbursement Landscape
4.3.1.3.1. Payer Mix
4.3.1.3.2. Reimbursement Process
4.3.2. The Canadian Scenario
4.3.2.1. Regulatory Authority
4.3.2.2. Review / Approval Process
4.3.2.3. Reimbursement Landscape
4.3.2.3.1. Payer Mix
4.3.2.3.2. Reimbursement Process
4.4. Regulatory and Reimbursement Landscape in Europe
4.4.1. Overall Scenario
4.4.1.1. Regulatory Authority
4.4.1.2. Review / Approval Process
4.4.2. The UK Scenario
4.4.2.1. Reimbursement Landscape
4.4.2.1.1. Payer Mix
4.4.2.1.2. Reimbursement Process
4.4.3. The German Scenario
4.4.3.1. Reimbursement Landscape
4.4.3.1.1. Payer Mix
4.4.3.1.2. Reimbursement Process
4.4.4. The French Scenario
4.4.4.1. Reimbursement Landscape
4.4.4.1.1. Payer Mix
4.4.4.1.2. Reimbursement Process
4.4.5. The Spanish Scenario
4.4.5.1. Reimbursement Landscape
4.4.5.1.1. Payer Mix
4.4.5.1.2. Reimbursement Process
4.4.6. The Italian Scenario
4.4.6.1. Reimbursement Landscape
4.4.6.1.1 Payer Mix
4.4.6.1.2. Reimbursement Process
4.5. Regulatory and Regulatory Landscape in Asia-Pacific
4.5.1. The Australian Scenario
4.5.1.1. Regulatory Authority
4.5.1.2. Review / Approval Process
4.5.1.3. Reimbursement Landscape
4.5.1.3.1. Payer Mix
4.5.1.3.2. Reimbursement Process
4.5.2. The Chinese Scenario
4.5.2.1. Regulatory Authority
4.5.2.2. Review / Approval Process
4.5.2.3. Reimbursement Landscape
4.5.2.3.1. Payer Mix
4.5.2.3.2. Reimbursement Process
4.5.3. The Japanese Scenario
4.5.3.1. Regulatory Authority
4.5.3.2. Review / Approval Process
4.5.3.3. Reimbursement Landscape
4.5.3.3.1. Payer Mix
4.5.3.3.2. Reimbursement Process
5. CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Neurostimulation Devices: Overall Market Landscape
5.2.1. Distribution by Year of Establishment
5.2.2. Distribution by Geographical Location
5.2.3. Distribution by Size of Developers
5.2.4. Distribution by Developers
5.2.5. Distribution by Type of Devices
5.2.6. Distribution by Target Nerve
5.2.7. Distribution by Therapeutic Areas
5.2.8. Distribution by Development / Approval Status
5.2.9. Distribution by Size
5.2.10. Distribution by Weight
5.2.11. Distribution by Battery Type
5.2.12. Distribution by Battery Longevity
5.2.13. Distribution by Number of Electrodes
5.2.14. Distribution by MRI Compatibility
6. SPINAL CORD STIMULATION
6.1. Chapter Overview
6.2. Overview of SCS Devices
6.2.1. Historical Development
6.2.2. Associated Surgical Procedures
6.3. Device Competitiveness Analysis
6.4. Key Device Developers
6.4.1. Medtronic
6.4.1.1. Chapter Overview
6.4.1.2. Financial Information
6.4.1.3. Device Description: Intellis™
6.4.1.4. Recent Developments and Future Outlook
6.4.2. Boston Scientific
6.4.2.1. Chapter Overview
6.4.2.2. Financial Information
6.4.2.3. Device Description: Precision™ Plus
6.4.2.4. Recent Developments and Future Outlook
6.4.3. Stimwave
6.4.3.1. Chapter Overview
6.4.3.2. Financial Information
6.4.3.3. Device Description: Freedom-8A, Freedom-4
6.4.3.4. Recent Developments and Future Outlook
6.4.4. Nevro
6.4.4.1. Chapter Overview
6.4.4.2. Financial Information
6.4.4.3. Device Description: Senza®
6.4.4.4. Recent Developments and Future Outlook
7. DEEP BRAIN STIMULATION
7.1. Chapter Overview
7.2. Overview of DBS Devices
7.2.1. Historical Development
7.2.2. Associated Surgical Procedures
7.3. Device Competitiveness Analysis
7.4. Key Device Developers
7.4.1. Medtronic
7.4.1.1. Chapter Overview
7.4.1.2. Financial Information
7.4.1.3. Device Description: Activa™ PC, Activa™ SC, Activa™ RC
7.4.1.4. Recent Developments and Future Outlook
7.4.2. Boston Scientific
7.4.2.1. Chapter Overview
7.4.2.2. Financial Information
7.4.2.3. Device Description: Vercise™ DBS, Vercise Gevia™
7.4.2.4. Recent Developments and Future Outlook
7.4.3. Beijing PINS Medical
7.4.3.1. Chapter Overview
7.4.3.2. Financial Information
7.4.3.3. Device Description: PINS™ DBS System
7.4.3.4. Recent Developments and Future Outlook
7.4.4. Abbott (St. Jude Medical)
7.4.4.1. Chapter Overview
7.4.4.2. Financial Information
7.4.4.3. Device Description: Brio™
7.4.4.4. Recent Developments and Future Outlook
8. PERIPHERAL NERVE STIMULATION
8.1. Chapter Overview
8.2. Overview of PNS Devices
8.2.1. Historical Development
8.2.2. Associated Surgical Procedures
8.3. Spinal Nerve Stimulation
8.3.1. Device Competitiveness Analysis
8.3.2. Key Device Developers
8.3.2.1. Axonics Modulation Technologies
8.3.2.1.1. Chapter Overview
8.3.2.1.2. Financial Information
8.3.2.1.3. Device Description: Axonics® r-SNM™ System
8.3.2.1.4. Recent Developments and Future Outlook
8.3.2.2. BrainsGate
8.3.2.2.1. Chapter Overview
8.3.2.2.2. Financial Information
8.3.2.2.3. Device Description: Ischemic Stroke System™
8.3.2.2.4. Recent Developments and Future Outlook
8.3.2.3. Medtronic
8.3.2.3.1. Chapter Overview
8.3.2.3.2. Financial Information
8.3.2.3.3. Device Description: InterStim II
8.3.2.3.4. Recent Developments and Future Outlook
8.4. Vagus Nerve Stimulation
8.4.1. Device Competitiveness Analysis
8.4.2. Key Device Developers
8.4.2.1. LivaNova
8.4.2.1.1. Chapter Overview
8.4.2.1.2. Financial Information
8.4.2.1.3. Device Description: Pulse, Pulse Duo, AspireHC®, AspireSR®, SenTiva®
8.4.2.1.4. Recent Developments and Future Outlook
8.4.2.2. SetPoint Medical
8.4.2.2.1. Chapter Overview
8.4.2.2.2. Financial Information
8.4.2.2.3. Device Description: Unnamed Bioelectronic Platform
8.4.2.2.4. Recent Developments and Future Outlook
8.4.2.3. Synergia Medical
8.4.2.3.1. Chapter Overview
8.4.2.3.2. Financial Information
8.4.2.3.3. Device Description: NAOS Platform
8.4.2.3.4. Recent Developments and Future Outlook
8.5. Other Cranial Nerve Stimulation
8.5.1. Device Competitiveness Analysis
8.5.2. Key Device Developers
8.5.2.1. Bioness
8.5.2.1.1. Chapter Overview
8.5.2.1.2. Device Description: StimRouter®
8.5.2.1.3. Recent Developments and Future Outlook
8.5.2.2. Medtronic
8.5.2.2.1. Chapter Overview
8.5.2.2.2. Financial Information
8.5.2.2.3. Device Description: Intellis™
8.5.2.2.4. Recent Developments and Future Outlook
8.5.2.3. Nyxoah
8.5.2.3.1. Chapter Overview
8.5.2.3.2. Financial Information
8.5.2.3.3. Device Description: Genio™
8.5.2.3.4. Recent Developments and Future Outlook
8.5.2.4. BlueWind Medical
8.5.2.4.1. Chapter Overview
8.5.2.4.2. Device Description: RENOVA™, VIVENDI™
8.5.2.4.3. Recent Developments and Future Outlook
9. BRAND POSITIONING ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Brand Positioning Matrices of Key Industry Players
9.3.1. Abbott (St. Jude Medical)
9.3.2. Boston Scientific
9.3.3. LivaNova
9.3.4. Medtronic
9.3.5. Stimwave
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Neurostimulation Devices: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Geographical Location
10.3.3. Analysis by CPC Classifications
10.3.4. Emerging Areas
10.3.5. Leading Players by Number of Patents
10.4. Neurostimulation Devices: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.4.1.1. Boston Scientific and Medtronic
10.4.1.2. Other Leading Patent Assignees
10.4.2. Analysis by Geographical Distribution
10.5. Neurostimulation Devices: Patent Valuation Analysis
10.6. Leading Patents by Number of Citations
11. CLINICAL TRIAL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Neurostimulation Devices: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Geographical Analysis by Number of Clinical Trials
11.3.3. Geographical Analysis Enrolled Patient Population
11.3.4. Analysis by Trial Recruitment Status
11.3.5. Analysis by Type of Sponsors / Collaborators
11.3.6. Most Active Players in terms of Number of Trials
11.3.7. Analysis by Focus Area of Trials
11.3.8. Leading Indications in terms of Number of Trials
12. COLLABORATIONS AND PARTNERSHIPS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Neurostimulation Devices: Recent Collaborations and Partnerships
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Type of Device
12.3.4. Most Active Players by Number of Partnerships
12.3.5. Analysis by Geographical Regions
12.3.5.1. Most Active Players
12.3.5.2. Intercontinental and Intracontinental Agreements
13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. Neurostimulation Devices: Funding and Investment Analysis
13.3.1. Analysis by Number of Funding Instances
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Analysis by Number of Funding Instances and Amount Invested in Different Types of Devices
13.3.5. Most Active Players
13.3.6. Most Active Investors
13.4. Concluding Remarks
14. MARKET FORECAST
14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Global Neurostimulation Devices Market
14.3.1. Global Neurostimulation Devices Market, 2018-2030 (By Value)
14.3.2. Global Neurostimulation Devices Market, 2018-2030 (By Volume)
14.4. Global Neurostimulation Devices Market: Distribution by Type of Device, Indication and Geography
14.4.1. Global SCS Devices Market, 2018-2030 (By Value)
14.4.1.1. Global SCS Devices Market for Chronic Pain, 2018-2030 (By Value)
14.4.1.1.1. SCS Devices Market for Chronic Pain in the US, 2018-2030 (By Value)
14.4.1.1.2. SCS Devices Market for Chronic Pain in Canada, 2018-2030 (By Value)
14.4.1.1.3. SCS Devices Market for Chronic Pain in the UK, 2018-2030 (By Value)
14.4.1.1.4. SCS Devices Market for Chronic Pain in Germany, 2018-2030 (By Value)
14.4.1.1.5. SCS Devices Market for Chronic Pain in France, 2018-2030 (By Value)
14.4.1.1.6. SCS Devices Market for Chronic Pain in Spain, 2018-2030 (By Value)
14.4.1.1.7. SCS Devices Market for Chronic Pain in Italy, 2018-2030 (By Value)
14.4.1.1.8. SCS Devices Market for Chronic Pain in Australia, 2018-2030 (By Value)
14.4.1.1.9. SCS Devices Market for Chronic Pain in China, 2018-2030 (By Value)
14.4.1.1.10. SCS Devices Market for Chronic Pain in Japan, 2018-2030 (By Value)
14.4.2. Global SCS Devices Market, 2018-2030 (By Volume)
14.4.2.1. Global SCS Devices Market for Chronic Pain, 2018-2030 (By Volume)
14.4.2.1.1. SCS Devices Market for Chronic Pain in the US, 2018-2030 (By Volume)
14.4.2.1.2. SCS Devices Market for Chronic Pain in Canada, 2018-2030 (By Volume)
14.4.2.1.3. SCS Devices Market for Chronic Pain in the UK, 2018-2030 (By Volume)
14.4.2.1.4. SCS Devices Market for Chronic Pain in Germany, 2018-2030 (By Volume)
14.4.2.1.5. SCS Devices Market for Chronic Pain in France, 2018-2030 (By Volume)
14.4.2.1.6. SCS Devices Market for Chronic Pain in Spain, 2018-2030 (By Volume)
14.4.2.1.7. SCS Devices Market for Chronic Pain in Italy, 2018-2030 (By Volume)
14.4.2.1.8. SCS Devices Market for Chronic Pain in Australia, 2018-2030 (By Volume)
14.4.2.1.9. SCS Devices Market for Chronic Pain in China, 2018-2030 (By Volume)
14.4.2.1.10. SCS Devices Market for Chronic Pain in Japan, 2018-2030 (By Volume)
14.4.3. Global DBS Devices Market, 2018-2030 (By Value)
14.4.3.1. Global DBS Devices Market for Essential Tremor, 2018-2030 (By Value)
14.4.3.1.1. DBS Devices Market for Essential Tremor in the US, 2018-2030 (By Value)
14.4.3.1.2. DBS Devices Market for Essential Tremor in Canada, 2018-2030 (By Value)
14.4.3.1.3. DBS Devices Market for Essential Tremor in the UK, 2018-2030 (By Value)
14.4.3.1.4. DBS Devices Market for Essential Tremor in Germany, 2018-2030 (By Value)
14.4.3.1.5. DBS Devices Market for Essential Tremor in France, 2018-2030 (By Value)
14.4.3.1.6. DBS Devices Market for Essential Tremor in Spain, 2018-2030 (By Value)
14.4.3.1.7. DBS Devices Market for Essential Tremor in Italy, 2018-2030 (By Value)
14.4.3.1.8. DBS Devices Market for Essential Tremor in Australia, 2018-2030 (By Value)
14.4.3.1.9. DBS Devices Market for Essential Tremor in China, 2018-2030 (By Value)
14.4.3.1.10. DBS Devices Market for Essential Tremor in Japan, 2018-2030 (By Value)
14.4.3.2. Global DBS Devices Market for Parkinson’s Disease, 2018-2030 (By Value)
14.4.3.2.1. DBS Devices Market for Parkinson’s Disease in the US, 2018-2030 (By Value)
14.4.3.2.2. DBS Devices Market for Parkinson’s Disease in Canada, 2018-2030 (By Value)
14.4.3.2.3. DBS Devices Market for Parkinson’s Disease in the UK, 2018-2030 (By Value)
14.4.3.2.4. DBS Devices Market for Parkinson’s Disease in Germany, 2018-2030 (By Value)
14.4.3.2.5. DBS Devices Market for Parkinson’s Disease in France, 2018-2030 (By Value)
14.4.3.2.6. DBS Devices Market for Parkinson’s Disease in Spain, 2018-2030 (By Value)
14.4.3.2.7. DBS Devices Market for Parkinson’s Disease in Italy, 2018-2030 (By Value)
14.4.3.2.8. DBS Devices Market for Parkinson’s Disease in Australia, 2018-2030 (By Value)
14.4.3.2.9. DBS Devices Market for Parkinson’s Disease in China, 2018-2030 (By Value)
14.4.3.2.10. DBS Devices Market for Parkinson’s Disease in Japan, 2018-2030 (By Value)
14.4.3.3. Global DBS Devices Market for Dystonia, 2018-2030 (By Value)
14.4.3.3.1. DBS Devices Market for Dystonia in the US, 2018-2030 (By Value)
14.4.3.3.2. DBS Devices Market for Dystonia in Canada, 2018-2030 (By Value)
14.4.3.3.3. DBS Devices Market for Dystonia in the UK, 2018-2030 (By Value)
14.4.3.3.4. DBS Devices Market for Dystonia in Germany, 2018-2030 (By Value)
14.4.3.3.5. DBS Devices Market for Dystonia in France, 2018-2030 (By Value)
14.4.3.3.6. DBS Devices Market for Dystonia in Spain, 2018-2030 (By Value)
14.4.3.3.7. DBS Devices Market for Dystonia in Italy, 2018-2030 (By Value)
14.4.3.3.8. DBS Devices Market for Dystonia in Australia, 2018-2030 (By Value)
14.4.3.3.9. DBS Devices Market for Dystonia in China, 2018-2030 (By Value)
14.4.3.3.10. DBS Devices Market for Dystonia in Japan, 2018-2030 (By Value)
14.4.3.4. Global DBS Devices Market for Obsessive Compulsive Disorder, 2018-2030 (By Value)
14.4.3.4.1. DBS Devices Market for Obsessive Compulsive Disorder in the US, 2018-2030 (By Value)
14.4.3.4.2. DBS Devices Market for Obsessive Compulsive Disorder in Canada, 2018-2030 (By Value)
14.4.3.4.3. DBS Devices Market for Obsessive Compulsive Disorder in the UK, 2018-2030 (By Value)
14.4.3.4.4. DBS Devices Market for Obsessive Compulsive Disorder in Germany, 2018-2030 (By Value)
14.4.3.4.5. DBS Devices Market for Obsessive Compulsive Disorder in France, 2018-2030 (By Value)
14.4.3.4.6. DBS Devices Market for Obsessive Compulsive Disorder in Spain, 2018-2030 (By Value)
14.4.3.4.7. DBS Devices Market for Obsessive Compulsive Disorder in Italy, 2018-2030 (By Value)
14.4.3.4.8. DBS Devices Market for Obsessive Compulsive Disorder in Australia, 2018-2030 (By Value)
14.4.3.4.9. DBS Devices Market for Obsessive Compulsive Disorder in China, 2018-2030 (By Value)
14.4.3.4.10. DBS Devices Market for Obsessive Compulsive Disorder in Japan, 2018-2030 (By Value)
14.4.4. Global DBS Devices Market, 2018-2030 (By Volume)
14.4.4.1. Global DBS Devices Market for Essential Tremor, 2018-2030 (By Volume)
14.4.4.1.1. DBS Devices Market for Essential Tremor in the US, 2018-2030 (By Volume)
14.4.4.1.2. DBS Devices Market for Essential Tremor in Canada, 2018-2030 (By Volume)
14.4.4.1.3. DBS Devices Market for Essential Tremor in the UK, 2018-2030 (By Volume)
14.4.4.1.4. DBS Devices Market for Essential Tremor in Germany, 2018-2030 (By Volume)
14.4.4.1.5. DBS Devices Market for Essential Tremor in France, 2018-2030 (By Volume)
14.4.4.1.6. DBS Devices Market for Essential Tremor in Spain, 2018-2030 (By Volume)
14.4.4.1.7. DBS Devices Market for Essential Tremor in Italy, 2018-2030 (By Volume)
14.4.4.1.8. DBS Devices Market for Essential Tremor in Australia, 2018-2030 (By Volume)
14.4.4.1.9. DBS Devices Market for Essential Tremor in China, 2018-2030 (By Volume)
14.4.4.1.10. DBS Devices Market for Essential Tremor in Japan, 2018-2030 (By Volume)
14.4.4.2. Global DBS Devices Market for Parkinson’s Disease, 2018-2030 (By Volume)
14.4.4.2.1. DBS Devices Market for Parkinson’s Disease in the US, 2018-2030 (By Volume)
14.4.4.2.2. DBS Devices Market for Parkinson’s Disease in Canada, 2018-2030 (By Volume)
14.4.4.2.3. DBS Devices Market for Parkinson’s Disease in the UK, 2018-2030 (By Volume)
14.4.4.2.4. DBS Devices Market for Parkinson’s Disease in Germany, 2018-2030 (By Volume)
14.4.4.2.5. DBS Devices Market for Parkinson’s Disease in France, 2018-2030 (By Volume)
14.4.4.2.6. DBS Devices Market for Parkinson’s Disease in Spain, 2018-2030 (By Volume)
14.4.4.2.7. DBS Devices Market for Parkinson’s Disease in Italy, 2018-2030 (By Volume)
14.4.4.2.8. DBS Devices Market for Parkinson’s Disease in Australia, 2018-2030 (By Volume)
14.4.4.2.9. DBS Devices Market for Parkinson’s Disease in China, 2018-2030 (By Volume)
14.4.4.2.10. DBS Devices Market for Parkinson’s Disease in Japan, 2018-2030 (By Volume)
14.4.4.3. Global DBS Devices Market for Dystonia, 2018-2030 (By Volume)
14.4.4.3.1. DBS Devices Market for Dystonia in the US, 2018-2030 (By Volume)
14.4.4.3.2. DBS Devices Market for Dystonia in Canada, 2018-2030 (By Volume)
14.4.4.3.3. DBS Devices Market for Dystonia in the UK, 2018-2030 (By Volume)
14.4.4.3.4. DBS Devices Market for Dystonia in Germany, 2018-2030 (By Volume)
14.4.4.3.5. DBS Devices Market for Dystonia in France, 2018-2030 (By Volume)
14.4.4.3.6. DBS Devices Market for Dystonia in Spain, 2018-2030 (By Volume)
14.4.4.3.7. DBS Devices Market for Dystonia in Italy, 2018-2030 (By Volume)
14.4.4.3.8. DBS Devices Market for Dystonia in Australia, 2018-2030 (By Volume)
14.4.4.3.9. DBS Devices Market for Dystonia in China, 2018-2030 (By Volume)
14.4.4.3.10. DBS Devices Market for Dystonia in Japan, 2018-2030 (By Volume)
14.4.4.4. Global DBS Devices Market for Obsessive Compulsive Disorder, 2018-2030 (By Volume)
14.4.4.4.1. DBS Devices Market for Obsessive Compulsive Disorder in the US, 2018-2030 (By Volume)
14.4.4.4.2. DBS Devices Market for Obsessive Compulsive Disorder in Canada, 2018-2030 (By Volume)
14.4.4.4.3. DBS Devices Market for Obsessive Compulsive Disorder in the UK, 2018-2030 (By Volume)
14.4.4.4.4. DBS Devices Market for Obsessive Compulsive Disorder in Germany, 2018-2030 (By Volume)
14.4.4.4.5. DBS Devices Market for Obsessive Compulsive Disorder in France, 2018-2030 (By Volume)
14.4.4.4.6. DBS Devices Market for Obsessive Compulsive Disorder in Spain, 2018-2030 (By Volume)
14.4.4.4.7. DBS Devices Market for Obsessive Compulsive Disorder in Italy, 2018-2030 (By Volume)
14.4.4.4.8. DBS Devices Market for Obsessive Compulsive Disorder in Australia, 2018-2030 (By Volume)
14.4.4.4.9. DBS Devices Market for Obsessive Compulsive Disorder in China, 2018-2030 (By Volume)
14.4.4.4.10. DBS Devices Market for Obsessive Compulsive Disorder in Japan, 2018-2030 (By Volume)
14.4.5. Global VNS Devices Market, 2018-2030 (By Value)
14.4.5.1. Global VNS Devices Market for Epilepsy, 2018-2030 (By Value)
14.4.5.1.1. VNS Devices Market for Epilepsy in the US, 2018-2030 (By Value)
14.4.5.1.2. VNS Devices Market for Epilepsy in Canada, 2018-2030 (By Value)
14.4.5.1.3. VNS Devices Market for Epilepsy in the UK, 2018-2030 (By Value)
14.4.5.1.4. VNS Devices Market for Epilepsy in Germany, 2018-2030 (By Value)
14.4.5.1.5. VNS Devices Market for Epilepsy in France, 2018-2030 (By Value)
14.4.5.1.6. VNS Devices Market for Epilepsy in Spain, 2018-2030 (By Value)
14.4.5.1.7. VNS Devices Market for Epilepsy in Italy, 2018-2030 (By Value)
14.4.5.1.8. VNS Devices Market for Epilepsy in Australia, 2018-2030 (By Value)
14.4.5.1.9. VNS Devices Market for Epilepsy in China, 2018-2030 (By Value)
14.4.5.1.10. VNS Devices Market for Epilepsy in Japan, 2018-2030 (By Value)
14.4.5.2. Global VNS Devices Market for Major Depressive Disorder, 2018-2030 (By Value)
14.4.5.2.1. VNS Devices Market for Major Depressive Disorder in the US, 2018-2030 (By Value)
14.4.5.2.2. VNS Devices Market for Major Depressive Disorder in Canada, 2018-2030 (By Value)
14.4.5.2.3. VNS Devices Market for Major Depressive Disorder in the UK, 2018-2030 (By Value)
14.4.5.2.4. VNS Devices Market for Major Depressive Disorder in Germany, 2018-2030 (By Value)
14.4.5.2.5. VNS Devices Market for Major Depressive Disorder in France, 2018-2030 (By Value)
14.4.5.2.6. VNS Devices Market for Major Depressive Disorder in Spain, 2018-2030 (By Value)
14.4.5.2.7. VNS Devices Market for Major Depressive Disorder in Italy, 2018-2030 (By Value)
14.4.5.2.8. VNS Devices Market for Major Depressive Disorder in Australia, 2018-2030 (By Value)
14.4.5.2.9. VNS Devices Market for Major Depressive Disorder in China, 2018-2030 (By Value)
14.4.5.2.10. VNS Devices Market for Major Depressive Disorder in Japan, 2018-2030 (By Value)
14.4.6. Global VNS Devices Market, 2018-2030 (By Volume)
14.4.6.1. Global VNS Devices Market for Epilepsy, 2018-2030 (By Volume)
14.4.6.1.1. VNS Devices Market for Epilepsy in the US, 2018-2030 (By Volume)
14.4.6.1.2. VNS Devices Market for Epilepsy in Canada, 2018-2030 (By Volume)
14.4.6.1.3. VNS Devices Market for Epilepsy in the UK, 2018-2030 (By Volume)
14.4.6.1.4. VNS Devices Market for Epilepsy in Germany, 2018-2030 (By Volume)
14.4.6.1.5. VNS Devices Market for Epilepsy in France, 2018-2030 (By Volume)
14.4.6.1.6. VNS Devices Market for Epilepsy in Spain, 2018-2030 (By Volume)
14.4.6.1.7. VNS Devices Market for Epilepsy in Italy, 2018-2030 (By Volume)
14.4.6.1.8. VNS Devices Market for Epilepsy in Australia, 2018-2030 (By Volume)
14.4.6.1.9. VNS Devices Market for Epilepsy in China, 2018-2030 (By Volume)
14.4.6.1.10. VNS Devices Market for Epilepsy in Japan, 2018-2030 (By Volume)
14.4.6.2. Global VNS Devices Market for Major Depressive Disorder, 2018-2030 (By Volume)
14.4.6.2.1. VNS Devices Market for Major Depressive Disorder in the US, 2018-2030 (By Volume)
14.4.6.2.2. VNS Devices Market for Major Depressive Disorder in Canada, 2018-2030 (By Volume)
14.4.6.2.3. VNS Devices Market for Major Depressive Disorder in the UK, 2018-2030 (By Volume)
14.4.6.2.4. VNS Devices Market for Major Depressive Disorder in Germany, 2018-2030 (By Volume)
14.4.6.2.5. VNS Devices Market for Major Depressive Disorder in France, 2018-2030 (By Volume)
14.4.6.2.6. VNS Devices Market for Major Depressive Disorder in Spain, 2018-2030 (By Volume)
14.4.6.2.7. VNS Devices Market for Major Depressive Disorder in Italy, 2018-2030 (By Volume)
14.4.6.2.8. VNS Devices Market for Major Depressive Disorder in Australia, 2018-2030 (By Volume)
14.4.6.2.9. VNS Devices Market for Major Depressive Disorder in China, 2018-2030 (By Volume)
14.4.6.2.10. VNS Devices Market for Major Depressive Disorder in Japan, 2018-2030 (By Volume)
14.4.7. Global Other Neurostimulation Devices Market, 2018-2030 (By Value)
14.4.7.1. Global Other Neurostimulation Devices Market for Overactive Bladder, 2018-2030 (By Value)
14.4.7.1.1. Other Neurostimulation Devices Market for Overactive Bladder in the US, 2018-2030 (By Value)
14.4.7.1.2. Other Neurostimulation Devices Market for Overactive Bladder in Canada, 2018-2030 (By Value)
14.4.7.1.3. Other Neurostimulation Devices Market for Overactive Bladder in the UK, 2018-2030 (By Value)
14.4.7.1.4. Other Neurostimulation Devices Market for Overactive Bladder in Germany, 2018-2030 (By Value)
14.4.7.1.5. Other Neurostimulation Devices Market for Overactive Bladder in France, 2018-2030 (By Value)
14.4.7.1.6. Other Neurostimulation Devices Market for Overactive Bladder in Spain, 2018-2030 (By Value)
14.4.7.1.7. Other Neurostimulation Devices Market for Overactive Bladder in Italy, 2018-2030 (By Value)
14.4.7.1.8. Other Neurostimulation Devices Market for Overactive Bladder in Australia, 2018-2030 (By Value)
14.4.7.1.9. Other Neurostimulation Devices Market for Overactive Bladder in China, 2018-2030 (By Value)
14.4.7.1.10. Other Neurostimulation Devices Market for Overactive Bladder in Japan, 2018-2030 (By Value)
14.4.7.2. Global Other Neurostimulation Devices Market for Heart Failure, 2018-2030 (By Value)
14.4.7.2.1. Other Neurostimulation Devices Market for Heart Failure in the US, 2018-2030 (By Value)
14.4.7.2.2. Other Neurostimulation Devices Market for Heart Failure in Canada, 2018-2030 (By Value)
14.4.7.2.3. Other Neurostimulation Devices Market for Heart Failure in the UK, 2018-2030 (By Value)
14.4.7.2.4. Other Neurostimulation Devices Market for Heart Failure in Germany, 2018-2030 (By Value)
14.4.7.2.5. Other Neurostimulation Devices Market for Heart Failure in France, 2018-2030 (By Value)
14.4.7.2.6. Other Neurostimulation Devices Market for Heart Failure in Spain, 2018-2030 (By Value)
14.4.7.2.7. Other Neurostimulation Devices Market for Heart Failure in Italy, 2018-2030 (By Value)
14.4.7.2.8. Other Neurostimulation Devices Market for Heart Failure in Australia, 2018-2030 (By Value)
14.4.7.2.9. Other Neurostimulation Devices Market for Heart Failure in China, 2018-2030 (By Value)
14.4.7.2.10. Other Neurostimulation Devices Market for Heart Failure in Japan, 2018-2030 (By Value)
14.4.7.3. Global Other Neurostimulation Devices Market for Sleep Apnea, 2018-2030 (By Value)
14.4.7.3.1. Other Neurostimulation Devices Market for Sleep Apnea in the US, 2018-2030 (By Value)
14.4.7.3.2. Other Neurostimulation Devices Market for Sleep Apnea in Canada, 2018-2030 (By Value)
14.4.7.3.3. Other Neurostimulation Devices Market for Sleep Apnea in the UK, 2018-2030 (By Value)
14.4.7.3.4. Other Neurostimulation Devices Market for Sleep Apnea in Germany, 2018-2030 (By Value)
14.4.7.3.5. Other Neurostimulation Devices Market for Sleep Apnea in France, 2018-2030 (By Value)
14.4.7.3.6. Other Neurostimulation Devices Market for Sleep Apnea in Spain, 2018-2030 (By Value)
14.4.7.3.7. Other Neurostimulation Devices Market for Sleep Apnea in Italy, 2018-2030 (By Value)
14.4.7.3.8. Other Neurostimulation Devices Market for Sleep Apnea in Australia, 2018-2030 (By Value)
14.4.7.3.9. Other Neurostimulation Devices Market for Sleep Apnea in China, 2018-2030 (By Value)
14.4.7.3.10. Other Neurostimulation Devices Market for Sleep Apnea in Japan, 2018-2030 (By Value)
14.4.8. Global Other Neurostimulation Devices Market, 2018-2030 (By Volume)
14.4.8.1. Global Other Neurostimulation Devices Market for Overactive Bladder, 2018-2030 (By Volume)
14.4.8.1.1. Other Neurostimulation Devices Market for Overactive Bladder in the US, 2018-2030 (By Volume)
14.4.8.1.2. Other Neurostimulation Devices Market for Overactive Bladder in Canada, 2018-2030 (By Volume)
14.4.8.1.3. Other Neurostimulation Devices Market for Overactive Bladder in the UK, 2018-2030 (By Volume)
14.4.8.1.4. Other Neurostimulation Devices Market for Overactive Bladder in Germany, 2018-2030 (By Volume)
14.4.8.1.5. Other Neurostimulation Devices Market for Overactive Bladder in France, 2018-2030 (By Volume)
14.4.8.1.6. Other Neurostimulation Devices Market for Overactive Bladder in Spain, 2018-2030 (By Volume)
14.4.8.1.7. Other Neurostimulation Devices Market for Overactive Bladder in Italy, 2018-2030 (By Volume)
14.4.8.1.8. Other Neurostimulation Devices Market for Overactive Bladder in Australia, 2018-2030 (By Volume)
14.4.8.1.9. Other Neurostimulation Devices Market for Overactive Bladder in China, 2018-2030 (By Volume)
14.4.8.1.10. Other Neurostimulation Devices Market for Overactive Bladder in Japan, 2018-2030 (By Volume)
14.4.8.2. Global Other Neurostimulation Devices Market for Heart Failure, 2018-2030 (By Volume)
14.4.8.2.1. Other Neurostimulation Devices Market for Heart Failure in the US, 2018-2030 (By Volume)
14.4.8.2.2. Other Neurostimulation Devices Market for Heart Failure in Canada, 2018-2030 (By Volume)
14.4.8.2.3. Other Neurostimulation Devices Market for Heart Failure in the UK, 2018-2030 (By Volume)
14.4.8.2.4. Other Neurostimulation Devices Market for Heart Failure in Germany, 2018-2030 (By Volume)
14.4.8.2.5. Other Neurostimulation Devices Market for Heart Failure in France, 2018-2030 (By Volume)
14.4.8.2.6. Other Neurostimulation Devices Market for Heart Failure in Spain, 2018-2030 (By Volume)
14.4.8.2.7. Other Neurostimulation Devices Market for Heart Failure in Italy, 2018-2030 (By Volume)
14.4.8.2.8. Other Neurostimulation Devices Market for Heart Failure in Australia, 2018-2030 (By Volume)
14.4.8.2.9. Other Neurostimulation Devices Market for Heart Failure in China, 2018-2030 (By Volume)
14.4.8.2.10. Other Neurostimulation Devices Market for Heart Failure in Japan, 2018-2030 (By Volume)
14.4.8.3. Global Other Neurostimulation Devices Market for Sleep Apnea, 2018-2030 (By Volume)
14.4.8.3.1. Other Neurostimulation Devices Market for Sleep Apnea in the US, 2018-2030 (By Volume)
14.4.8.3.2. Other Neurostimulation Devices Market for Sleep Apnea in Canada, 2018-2030 (By Volume)
14.4.8.3.3. Other Neurostimulation Devices Market for Sleep Apnea in the UK, 2018-2030 (By Volume)
14.4.8.3.4. Other Neurostimulation Devices Market for Sleep Apnea in Germany, 2018-2030 (By Volume)
14.4.8.3.5. Other Neurostimulation Devices Market for Sleep Apnea in France, 2018-2030 (By Volume)
14.4.8.3.6. Other Neurostimulation Devices Market for Sleep Apnea in Spain, 2018-2030 (By Volume)
14.4.8.3.7. Other Neurostimulation Devices Market for Sleep Apnea in Italy, 2018-2030 (By Volume)
14.4.8.3.8. Other Neurostimulation Devices Market for Sleep Apnea in Australia, 2018-2030 (By Volume)
14.4.8.3.9. Other Neurostimulation Devices Market for Sleep Apnea in China, 2018-2030 (By Volume)
14.4.8.3.10. Other Neurostimulation Devices Market for Sleep Apnea in Japan, 2018-2030 (By Volume)
14.5. Global Neurostimulation Devices Market: Distribution by MRI Compatibility
14.5.1. Global MRI Compatible Neurostimulation Devices Market, 2018-2030 (By Value)
14.5.2. Global MRI Compatible Neurostimulation Devices Market, 2018-2030 (By Volume)
14.5.3. Global MRI Non-Compatible Neurostimulation Devices Market, 2018-2030 (By Value)
14.5.4. Global MRI Non-Compatible Neurostimulation Devices Market, 2018-2030 (By Volume)
15. FUTURE GROWTH OPPORTUNITIES
15.1. Chapter Overview
15.2. Development of Devices to Address the Needs of Unexplored Therapeutic Areas
15.3. Integration of Novel and Advanced Features in Devices
15.4. Launch / Commercialization of Devices Across Different Geographies
15.5. Increased Utilization of Real World Data Based Insights to Optimize Device Performance and Support Regulatory / Reimbursement Decisions
15.6. Implementation of Cybersecurity Measures to Tackle Device Hacks
16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. NeuroOne Medical Technologies
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Dave Rosa, President and Chief Executive Officer
16.3. ReShape Lifesciences
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Deborah Schmalz, Vice President, Regulatory Affairs, Clinical Research and Compliances, and Diane Utzman-O'Neill, Vice President, Marketing
16.4. Mainstay Medical
16.4.1. Company Snapshot
16.4.2. Interview Transcript: Jan Pieter Heemels, Vice President, Commercial Operations
16.5. Stimwave
16.5.1. Company Snapshot
16.5.2. Interview Transcript: Laura Tyler Perryman, Chief Executive Officer
16.6. WISE
16.6.1. Company Snapshot
16.6.2. Interview Transcript: Luca Ravagnan, Chief Executive Officer
16.7. Cardionomic
16.7.1. Company Snapshot
16.7.2. Interview Transcript: Steve Goedeke, President and Chief Executive Officer
17. APPENDIX 1: LIST OF NON-INVASIVE NEUROSTIMULATION DEVICES
18. APPENDIX 2: TABULATED DATA
19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Common Types of Neurological Disorders
Figure 3.2 DALYs and Deaths from Selected Neurological Disorders, 2015
Figure 3.3 Conventional Treatment Methods for Neurological Disorders
Figure 3.4 Historical Evolution of Neurostimulation Devices
Figure 3.5 Types of Neurostimulation Devices
Figure 3.6 Applications of Neurostimulation Devices
Figure 3.7 Growth Drivers and Roadblocks Related to Neurostimulation Devices
Figure 3.8 Neurostimulation Devices: Social Media Trends
Figure 4.1. US FDA: Review / Approval Process
Figure 4.2. Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
Figure 4.3. National Coverage Determination Process in the US
Figure 4.4. Health Canada: Review / Approval Process
Figure 4.5. Health Insurance Coverage in Canada: Distribution by Type of Coverage
Figure 4.6. Summary of CE Marking Process
Figure 4.7. Healthcare Insurance Coverage in the UK: Distribution by Type of Coverage
Figure 4.8. Reimbursement Process in the UK
Figure 4.9. Healthcare Insurance Coverage in Germany: Distribution by Type of Coverage
Figure 4.10. Reimbursement Process for In-patient Setting in Germany
Figure 4.11. Reimbursement Process for Out-patient Setting in Germany
Figure 4.12. Healthcare Insurance Coverage in France: Distribution by Type of Coverage
Figure 4.13. Reimbursement Process of Medical Devices Through LPPR
Figure 4.14. Healthcare Insurance Coverage in Spain: Distribution by Type of Coverage
Figure 4.15. Reimbursement Process of Medical Devices in Spain
Figure 4.16. Healthcare Insurance Coverage in Italy: Distribution by Type of Funding Sources
Figure 4.17. Reimbursement Process of Medical Devices in Italy
Figure 4.18. TGA: Review / Approval Process
Figure 4.19. Healthcare Insurance Coverage in Australia: Distribution by Type of Coverage
Figure 4.20. CFDA: Review / Approval Process
Figure 4.21. Healthcare Insurance Coverage in China: Distribution by Type of Coverage
Figure 4.22. Shanghai Reimbursement Approval Process
Figure 4.23. PMDA: Review / Approval Process
Figure 4.24. Snapshot of the Regulatory and Reimbursement Process in Japan
Figure 4.25. Healthcare Insurance Coverage in Japan: Distribution by Type of Coverage
Figure 4.26. Reimbursement Process of New Medical Devices in Japan
Figure 4.27. Bubble Analysis: Regional Regulatory Control Comparison
Figure 5.1 Neurostimulation Devices: Recent Activities
Figure 5.2 Neurostimulation Devices: Distribution of Industry Players by Year of Establishment
Figure 5.3 Neurostimulation Devices: Distribution of Industry Players by Geographical Location
Figure 5.4 Neurostimulation Devices: Distribution of Industry Players by Size (Employee Count)
Figure 5.5 Neurostimulation Devices: Leading Developers in terms of Number of Devices
Figure 5.6 Neurostimulation Devices: Distribution by Type of Devices
Figure 5.7 Neurostimulation Devices: Distribution by Type of Target Nerves
Figure 5.8 Neurostimulation Devices: Leading Target Indications in terms of Number of Devices
Figure 5.9 Neurostimulation Devices: Distribution by Type of Regulatory Approval
Figure 5.10 Neurostimulation Devices, Grid Analysis: Distribution by Device Approval Year, Target Therapeutic Area and Type of Device
Figure 5.11 Neurostimulation Devices: Distribution by Size
Figure 5.12 Neurostimulation Devices: Distribution by Weight
Figure 5.13 Neurostimulation Devices: Distribution by Battery Type
Figure 5.14 Neurostimulation Devices: Distribution by Battery Longevity
Figure 5.15 Neurostimulation Devices: Distribution by Number of Electrodes
Figure 5.16 Neurostimulation Devices: Distribution by MRI Compatibility
Figure 6.1. SCS Devices Competitiveness Analysis: Dot-Plot Representation
Figure 6.2. Medtronic: Net Sales, FY 2014-FY 2018 (USD Billion)
Figure 6.3. Medtronic, Net Sales: Distribution by Business Segments, FY 2018 (USD Billion)
Figure 6.4. Medtronic, Net Sales: Distribution by Region, FY 2018 (USD Billion)
Figure 6.5. Boston Scientific: Net Sales, FY 2013-H1 FY 2018 (USD Billion)
Figure 6.6. Boston Scientific, Net Sales: Distribution by Business Segments, FY 2017 (USD Billion)
Figure 6.7. Boston Scientific, Net Sales: Distribution by Region, FY 2017 (USD Billion)
Figure 6.8. Nevro: Revenues, FY 2013-Q1 FY 2018 (USD Million)
Figure 6.9. Nevro, Revenues: Distribution by Region, FY 2017 (USD Million)
Figure 7.1. DBS Devices Competitiveness Analysis: Dot-Plot Representation
Figure 7.2. Abbott: Net Sales, FY 2013-H1 FY 2018 (USD Billion)
Figure 7.3. Abbott, Net Sales: Distribution by Business Segments, FY 2017 (USD Billion)
Figure 7.4. Abbott, Net Sales: Distribution by Regions, FY 2017 (USD Billion)
Figure 8.1. SNS Devices Competitiveness Analysis: Dot-Plot Representation
Figure 8.2. VNS Devices Competitiveness Analysis: Dot-Plot Representation
Figure 8.3. LivaNova: Revenues, FY 2015-Q1 FY 2018 (USD Million)
Figure 8.4. LivaNova, Revenues: Distribution by Business Segments, FY 2017 (USD Million)
Figure 8.5. LivaNova, Revenues: Distribution by Regions, FY 2017 (USD Million)
Figure 8.6. Other CNS Devices Competitiveness Analysis: Dot-Plot Representation
Figure 9.1 Brand Positioning Analysis of Key Industry Players
Figure 9.2 Brand Positioning Matrix: Abbott (St. Jude Medical)
Figure 9.3 Brand Positioning Matrix: Boston Scientific
Figure 9.4 Brand Positioning Matrix: LivaNova
Figure 9.5 Brand Positioning Matrix: Medtronic
Figure 9.6 Brand Positioning Matrix: Stimwave
Figure 10.1 Patents: Distribution by Type
Figure 10.2 Patents: Cumulative Trend by Publication Year
Figure 10.3 Patents: Distribution by Geographical Location
Figure 10.4 Patents: Distribution by CPC Classifications (Top 20)
Figure 10.5 Patents: Emerging Areas
Figure 10.6 Patents: Distribution by Leading Players
Figure 10.7 Boston Scientific and Medtronic: Benchmarking by Patent Characteristics
Figure 10.8 Other Leading Patent Assignees: Benchmarking by Patent Characteristics
Figure 10.9 Industry Players: Benchmarking by Number of Patents Published Across Different Geographies
Figure10.10 Industry Players: Benchmarking by Number of International Patents
Figure 10.11 Patents: Distribution by Age (January 2010-June 2018)
Figure 10.12 Patent Valuation
Figure 11.1 Clinical Trials: Distribution by Trial Status
Figure 11.2 Clinical Trials: Distribution by Registration Year
Figure 11.3 Clinical Trials: Geographical Distribution by Number of Trials
Figure 11.4 Clinical Trials: Geographical Distribution by Enrolled Patient Population
Figure 11.5 Clinical Trials: Distribution by Registration Year and Recruitment Status
Figure 11.6 Clinical Trials: Geographical Distribution by Registration Year and Recruitment Status
Figure 11.7 Clinical Trials: Distribution by Type of Sponsors / Collaborators
Figure 11.8 Clinical Trials: Most Active Industry Players in terms of Number of Trials Conducted
Figure 11.9 Clinical Trials: Most Active Non-Industry Players in terms of Number of Trials Conducted
Figure 11.10 Clinical Trials: Focus Areas
Figure 11.11 Clinical Trials: Leading Indications in terms of Number of Trials
Figure 11.12 Clinical Trials: Year-wise Trend of Top Five Indications
Figure 12.1 Recent Partnerships: Cumulative Half Year-wise Trend (2015–H1 2018)
Figure 12.2 Recent Partnerships: Distribution by Type of Model
Figure 12.3 Recent Partnerships: Distribution by Year of Partnership and Type of Model
Figure 12.4 Recent Partnerships: Distribution by Type of Device
Figure 12.5 Recent Partnerships: Distribution by Year of Partnership and Type of Device
Figure 12.6 Recent Partnerships: Most Active Players
Figure 12.7 Recent Partnerships: Regional Distribution and Most Active Players
Figure 12.8 Recent Partnerships: Regional Distribution by Intercontinental and Intracontinental Agreements
Figure 13.1 Funding Instances: Cumulative Half Year-wise trend, January 2015-June 2018
Figure 13.2 Funding Instances: Cumulative Amount Invested, January 2015-June 2018 (USD Million)
Figure 13.3 Funding Instances: Distribution by Type of Funding, January 2015-June 2018
Figure 13.4 Funding Instances: Distribution by Amount Invested and Type of Funding, January 2015-June 2018 (USD Million)
Figure 13.5 Summary of Investments, January 2015-June 2018 (USD Million)
Figure 13.6 Funding Instances: Most Popular Device Types by Number of Instances, January 2015-June 2018
Figure 13.7 Funding Instances: Most Popular Device Types by Amount Invested, January 2015-June 2018 (USD Million)
Figure 13.8 Funding Instances: Distribution by Year of Investment and Type of Device, January 2015-June 2018 (USD Million)
Figure 13.9 Funding Instances: Most Active Players in terms of Number of Instances, January 2015-June 2018
Figure 13.10 Funding Instances: Most Active Players in terms of Amount Invested, January 2015-June 2018
Figure 13.11 Funding Instances: Most Active Investors in terms of Number of Instances, January 2015-June 2018
Figure 13.12 Funding Instances: Funding and Investment Summary
Figure 14.1 Global Neurostimulation Devices Market, 2018-2030 (USD Million)
Figure 14.2 Global Neurostimulation Devices Market, 2018-2030 (Units, Volume)
Figure 14.3 Global SCS Devices Market, 2018-2030 (USD Million)
Figure 14.4 Global SCS Devices Market for Chronic Pain, 2018-2030 (USD Million)
Figure 14.5 SCS Devices Market for Chronic Pain in the US, 2018-2030 (USD Million)
Figure 14.6 SCS Devices Market for Chronic Pain in Canada, 2018-2030 (USD Million)
Figure 14.7 SCS Devices Market for Chronic Pain in the UK, 2018-2030 (USD Million)
Figure 14.8 SCS Devices Market for Chronic Pain in Germany, 2018-2030 (USD Million)
Figure 14.9 SCS Devices Market for Chronic Pain in France, 2018-2030 (USD Million)
Figure 14.10 SCS Devices Market for Chronic Pain in Spain, 2018-2030 (USD Million)
Figure 14.11 SCS Devices Market for Chronic Pain in Italy, 2018-2030 (USD Million)
Figure 14.12 SCS Devices Market for Chronic Pain in Australia, 2018-2030 (USD Million)
Figure 14.13 SCS Devices Market for Chronic Pain in China, 2018-2030 (USD Million)
Figure 14.14 SCS Devices Market for Chronic Pain in Japan, 2018-2030 (USD Million)
Figure 14.15 Global SCS Devices Market, 2018-2030 (Units, Volume)
Figure 14.16 Global SCS Devices Market for Chronic Pain, 2018-2030 (Units, Volume)
Figure 14.17 SCS Devices Market for Chronic Pain in the US, 2018-2030 (Units, Volume)
Figure 14.18 SCS Devices Market for Chronic Pain in Canada, 2018-2030 (Units, Volume)
Figure 14.19 SCS Devices Market for Chronic Pain in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Figure 14.20 SCS Devices Market for Chronic Pain in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Figure 14.21 SCS Devices Market for Chronic Pain in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Figure 14.22 SCS Devices Market for Chronic Pain in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Figure 14.23 SCS Devices Market for Chronic Pain in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Figure 14.24 SCS Devices Market for Chronic Pain in Australia, 2018-2030 (Units, Volume)
Figure 14.25 SCS Devices Market for Chronic Pain in China, 2018-2030 (Units, Volume)
Figure 14.26 SCS Devices Market for Chronic Pain in Japan, 2018-2030 (Units, Volume)
Figure 14.27 Global DBS Devices Market, 2018-2030 (USD Million)
Figure 14.28 Global DBS Devices Market for Essential Tremor, 2018-2030 (USD Million)
Figure 14.29 DBS Devices Market for Essential Tremor in the US, 2018-2030 (USD Million)
Figure 14.30 DBS Devices Market for Essential Tremor in Canada, 2018-2030 (USD Million)
Figure 14.31 DBS Devices Market for Essential Tremor in the UK, 2018-2030 (USD Million)
Figure 14.32 DBS Devices Market for Essential Tremor in Germany, 2018-2030 (USD Million)
Figure 14.33 DBS Devices Market for Essential Tremor in France, 2018-2030 (USD Million)
Figure 14.34 DBS Devices Market for Essential Tremor in Spain, 2018-2030 (USD Million)
Figure 14.35 DBS Devices Market for Essential Tremor in Italy, 2018-2030 (USD Million)
Figure 14.36 DBS Devices Market for Essential Tremor in Australia, 2018-2030 (USD Million)
Figure 14.37 DBS Devices Market for Essential Tremor in China, 2018-2030 (USD Million)
Figure 14.38 DBS Devices Market for Essential Tremor in Japan, 2018-2030 (USD Million)
Figure 14.39 Global DBS Devices Market for Parkinson’s Disease, 2018-2030 (USD Million)
Figure 14.40 DBS Devices Market for Parkinson’s Disease in the US, 2018-2030 (USD Million)
Figure 14.41 DBS Devices Market for Parkinson’s Disease in Canada, 2018-2030 (USD Million)
Figure 14.42 DBS Devices Market for Parkinson’s Disease in the UK, 2018-2030 (USD Million)
Figure 14.43 DBS Devices Market for Parkinson’s Disease in Germany, 2018-2030 (USD Million)
Figure 14.44 DBS Devices Market for Parkinson’s Disease in France, 2018-2030 (USD Million)
Figure 14.45 DBS Devices Market for Parkinson’s Disease in Spain, 2018-2030 (USD Million)
Figure 14.46 DBS Devices Market for Parkinson’s Disease in Italy, 2018-2030 (USD Million)
Figure 14.47 DBS Devices Market for Parkinson’s Disease in Australia, 2018-2030 (USD Million)
Figure 14.48 DBS Devices Market for Parkinson’s Disease in China, 2018-2030 (USD Million)
Figure 14.49 DBS Devices Market for Parkinson’s Disease in Japan, 2018-2030 (USD Million)
Figure 14.50 Global DBS Devices Market for Dystonia, 2018-2030 (USD Million)
Figure 14.51 DBS Devices Market for Dystonia in the US, 2018-2030 (USD Million)
Figure 14.52 DBS Devices Market for Dystonia in Canada, 2018-2030 (USD Million)
Figure 14.53 DBS Devices Market for Dystonia in the UK, 2018-2030 (USD Million)
Figure 14.54 DBS Devices Market for Dystonia in Germany, 2018-2030 (USD Million)
Figure 14.55 DBS Devices Market for Dystonia in France, 2018-2030 (USD Million)
Figure 14.56 DBS Devices Market for Dystonia in Spain, 2018-2030 (USD Million)
Figure 14.57 DBS Devices Market for Dystonia in Italy, 2018-2030 (USD Million)
Figure 14.58 DBS Devices Market for Dystonia in Australia, 2018-2030 (USD Million)
Figure 14.59 DBS Devices Market for Dystonia in China, 2018-2030 (USD Million)
Figure 14.60 DBS Devices Market for Dystonia in Japan, 2018-2030 (USD Million)
Figure 14.61 Global DBS Devices Market for Obsessive Compulsive Disorder, 2018-2030 (USD Million)
Figure 14.62 DBS Devices Market for Obsessive Compulsive Disorder in the US, 2018-2030 (USD Million)
Figure 14.63 DBS Devices Market for Obsessive Compulsive Disorder in Canada, 2018-2030 (USD Million)
Figure 14.64 DBS Devices Market for Obsessive Compulsive Disorder in the UK, 2018-2030 (USD Million)
Figure 14.65 DBS Devices Market for Obsessive Compulsive Disorder in Germany, 2018-2030 (USD Million)
Figure 14.66 DBS Devices Market for Obsessive Compulsive Disorder in France, 2018-2030 (USD Million)
Figure 14.67 DBS Devices Market for Obsessive Compulsive Disorder in Spain, 2018-2030 (USD Million)
Figure 14.68 DBS Devices Market for Obsessive Compulsive Disorder in Italy, 2018-2030 (USD Million)
Figure 14.69 DBS Devices Market for Obsessive Compulsive Disorder in Australia, 2018-2030 (USD Million)
Figure 14.70 DBS Devices Market for Obsessive Compulsive Disorder in China, 2018-2030 (USD Million)
Figure 14.71 DBS Devices Market for Obsessive Compulsive Disorder in Japan, 2018-2030 (USD Million)
Figure 14.72 Global DBS Devices Market, 2018-2030 (Units, Volume)
Figure 14.73 Global DBS Devices Market for Essential Tremor, 2018-2030 (Units, Volume)
Figure 14.74 DBS Devices Market for Essential Tremor in the US, 2018-2030 (Units, Volume)
Figure 14.75 DBS Devices Market for Essential Tremor in Canada, 2018-2030 (Units, Volume)
Figure 14.76 DBS Devices Market for Essential Tremor in the UK, 2018-2030 (Units, Volume)
Figure 14.77 DBS Devices Market for Essential Tremor in Germany, 2018-2030 (Units, Volume)
Figure 14.78 DBS Devices Market for Essential Tremor in France, 2018-2030 (Units, Volume)
Figure 14.79 DBS Devices Market for Essential Tremor in Spain, 2018-2030 (Units, Volume)
Figure 14.80 DBS Devices Market for Essential Tremor in Italy, 2018-2030 (Units, Volume)
Figure 14.81 DBS Devices Market for Essential Tremor in Australia, 2018-2030 (Units, Volume)
Figure 14.82 DBS Devices Market for Essential Tremor in China, 2018-2030 (Units, Volume)
Figure 14.83 DBS Devices Market for Essential Tremor in Japan, 2018-2030 (Units, Volume)
Figure 14.84 Global DBS Devices Market for Parkinson’s Disease, 2018-2030 (Units, Volume)
Figure 14.85 DBS Devices Market for Parkinson’s Disease in the US, 2018-2030 (Units, Volume)
Figure 14.86 DBS Devices Market for Parkinson’s Disease in Canada, 2018-2030 (Units, Volume)
Figure 14.87 DBS Devices Market for Parkinson’s Disease in the UK, 2018-2030 (Units, Volume)
Figure 14.88 DBS Devices Market for Parkinson’s Disease in Germany, 2018-2030 (Units, Volume)
Figure 14.89 DBS Devices Market for Parkinson’s Disease in France, 2018-2030 (Units, Volume)
Figure 14.90 DBS Devices Market for Parkinson’s Disease in Spain, 2018-2030 (Units, Volume)
Figure 14.91 DBS Devices Market for Parkinson’s Disease in Italy, 2018-2030 (Units, Volume)
Figure 14.92 DBS Devices Market for Parkinson’s Disease in Australia, 2018-2030 (Units, Volume)
Figure 14.93 DBS Devices Market for Parkinson’s Disease in China, 2018-2030 (Units, Volume)
Figure 14.94 DBS Devices Market for Parkinson’s Disease in Japan, 2018-2030 (Units, Volume)
Figure 14.95 Global DBS Devices Market for Dystonia, 2018-2030 (Units, Volume)
Figure 14.96 DBS Devices Market for Dystonia in the US, 2018-2030 (Units, Volume)
Figure 14.97 DBS Devices Market for Dystonia in Canada, 2018-2030 (Units, Volume)
Figure 14.98 DBS Devices Market for Dystonia in the UK, 2018-2030 (Units, Volume)
Figure 14.99 DBS Devices Market for Dystonia in Germany, 2018-2030 (Units, Volume)
Figure 14.100 DBS Devices Market for Dystonia in France, 2018-2030 (Units, Volume)
Figure 14.101 DBS Devices Market for Dystonia in Spain, 2018-2030 (Units, Volume)
Figure 14.102 DBS Devices Market for Dystonia in Italy, 2018-2030 (Units, Volume)
Figure 14.103 DBS Devices Market for Dystonia in Australia, 2018-2030 (Units, Volume)
Figure 14.104 DBS Devices Market for Dystonia in China, 2018-2030 (Units, Volume)
Figure 14.105 DBS Devices Market for Dystonia in Japan, 2018-2030 (Units, Volume)
Figure 14.106 Global DBS Devices Market for Obsessive Compulsive Disorder, 2018-2030 (Units, Volume)
Figure 14.107 DBS Devices Market for Obsessive Compulsive Disorder in the US, 2018-2030 (Units, Volume)
Figure 14.108 DBS Devices Market for Obsessive Compulsive Disorder in Canada, 2018-2030 (Units, Volume)
Figure 14.109 DBS Devices Market for Obsessive Compulsive Disorder in the UK, 2018-2030 (Units, Volume)
Figure 14.110 DBS Devices Market for Obsessive Compulsive Disorder in Germany, 2018-2030 (Units, Volume)
Figure 14.111 DBS Devices Market for Obsessive Compulsive Disorder in France, 2018-2030 (Units, Volume)
Figure 14.112 DBS Devices Market for Obsessive Compulsive Disorder in Spain, 2018-2030 (Units, Volume)
Figure 14.113 DBS Devices Market for Obsessive Compulsive Disorder in Italy, 2018-2030 (Units, Volume)
Figure 14.114 DBS Devices Market for Obsessive Compulsive Disorder in Australia, 2018-2030 (Units, Volume)
Figure 14.115 DBS Devices Market for Obsessive Compulsive Disorder in China, 2018-2030 (Units, Volume)
Figure 14.116 DBS Devices Market for Obsessive Compulsive Disorder in Japan, 2018-2030 (Units, Volume)
Figure 14.117 Global VNS Devices Market, 2018-2030 (USD Million)
Figure 14.118 Global VNS Devices Market for Epilepsy, 2018-2030 (USD Million)
Figure 14.119 VNS Devices Market for Epilepsy in the US, 2018-2030 (USD Million)
Figure 14.120 VNS Devices Market for Epilepsy in Canada, 2018-2030 (USD Million)
Figure 14.121 VNS Devices Market for Epilepsy in the UK, 2018-2030 (USD Million)
Figure 14.122 VNS Devices Market for Epilepsy in Germany, 2018-2030 (USD Million)
Figure 14.123 VNS Devices Market for Epilepsy in France, 2018-2030 (USD Million)
Figure 14.124 VNS Devices Market for Epilepsy in Spain, 2018-2030 (USD Million)
Figure 14.125 VNS Devices Market for Epilepsy in Italy, 2018-2030 (USD Million)
Figure 14.126 VNS Devices Market for Epilepsy in Australia, 2018-2030 (USD Million)
Figure 14.127 VNS Devices Market for Epilepsy in China, 2018-2030 (USD Million)
Figure 14.128 VNS Devices Market for Epilepsy in Japan, 2018-2030 (USD Million)
Figure 14.129 Global VNS Devices Market for Major Depressive Disorder, 2018-2030 (USD Million)
Figure 14.130 VNS Devices Market for Major Depressive Disorder in the US, 2018-2030 (USD Million)
Figure 14.131 VNS Devices Market for Major Depressive Disorder in Canada, 2018-2030 (USD Million)
Figure 14.132 VNS Devices Market for Major Depressive Disorder in the UK, 2018-2030 (USD Million)
Figure 14.133 VNS Devices Market for Major Depressive Disorder in Germany, 2018-2030 (USD Million)
Figure 14.134 VNS Devices Market for Major Depressive Disorder in France, 2018-2030 (USD Million)
Figure 14.135 VNS Devices Market for Major Depressive Disorder in Spain, 2018-2030 (USD Million)
Figure 14.136 VNS Devices Market for Major Depressive Disorder in Italy, 2018-2030 (USD Million)
Figure 14.137 VNS Devices Market for Major Depressive Disorder in Australia, 2018-2030 (USD Million)
Figure 14.138 VNS Devices Market for Major Depressive Disorder in China, 2018-2030 (USD Million)
Figure 14.139 VNS Devices Market for Major Depressive Disorder in Japan, 2018-2030 (USD Million)
Figure 14.140 Global VNS Devices Market, 2018-2030 (Units, Volume)
Figure 14.141 Global VNS Devices Market for Epilepsy, 2018-2030 (Units, Volume)
Figure 14.142 VNS Devices Market for Epilepsy in the US, 2018-2030 (Units, Volume)
Figure 14.143 VNS Devices Market for Epilepsy in Canada, 2018-2030 (Units, Volume)
Figure 14.144 VNS Devices Market for Epilepsy in the UK, 2018-2030 (Units, Volume)
Figure 14.145 VNS Devices Market for Epilepsy in Germany, 2018-2030 (Units, Volume)
Figure 14.146 VNS Devices Market for Epilepsy in France, 2018-2030 (Units, Volume)
Figure 14.147 VNS Devices Market for Epilepsy in Spain, 2018-2030 (Units, Volume)
Figure 14.148 VNS Devices Market for Epilepsy in Italy, 2018-2030 (Units, Volume)
Figure 14.149 VNS Devices Market for Epilepsy in Australia, 2018-2030 (Units, Volume)
Figure 14.150 VNS Devices Market for Epilepsy in China, 2018-2030 (Units, Volume)
Figure 14.151 VNS Devices Market for Epilepsy in Japan, 2018-2030 (Units, Volume)
Figure 14.152 Global VNS Devices Market for Major Depressive Disorder, 2018-2030 (Units, Volume)
Figure 14.153 VNS Devices Market for Major Depressive Disorder in the US, 2018-2030 (Units, Volume)
Figure 14.154 VNS Devices Market for Major Depressive Disorder in Canada, 2018-2030 (Units, Volume)
Figure 14.155 VNS Devices Market for Major Depressive Disorder in the UK, 2018-2030 (Units, Volume)
Figure 14.156 VNS Devices Market for Major Depressive Disorder in Germany, 2018-2030 (Units, Volume)
Figure 14.157 VNS Devices Market for Major Depressive Disorder in France, 2018-2030 (Units, Volume)
Figure 14.158 VNS Devices Market for Major Depressive Disorder in Spain, 2018-2030 (Units, Volume)
Figure 14.159 VNS Devices Market for Major Depressive Disorder in Italy, 2018-2030 (Units, Volume)
Figure 14.160 VNS Devices Market for Major Depressive Disorder in Australia, 2018-2030 (Units, Volume)
Figure 14.161 VNS Devices Market for Major Depressive Disorder in China, 2018-2030 (Units, Volume)
Figure 14.162 VNS Devices Market for Major Depressive Disorder in Japan, 2018-2030 (Units, Volume)
Figure 14.163 Global Other Neurostimulation Devices Market, 2018-2030 (USD Million)
Figure 14.164 Global Other Neurostimulation Devices Market for Overactive Bladder, 2018-2030 (USD Million)
Figure 14.165 Other Neurostimulation Devices Market for Overactive Bladder in the US, 2018-2030 (USD Million)
Figure 14.166 Other Neurostimulation Devices Market for Overactive Bladder in Canada, 2018-2030 (USD Million)
Figure 14.167 Other Neurostimulation Devices Market for Overactive Bladder in the UK, 2018-2030 (USD Million)
Figure 14.168 Other Neurostimulation Devices Market for Overactive Bladder in Germany, 2018-2030 (USD Million)
Figure 14.169 Other Neurostimulation Devices Market for Overactive Bladder in France, 2018-2030 (USD Million)
Figure 14.170 Other Neurostimulation Devices Market for Overactive Bladder in Spain, 2018-2030 (USD Million)
Figure 14.171 Other Neurostimulation Devices Market for Overactive Bladder in Italy, 2018-2030 (USD Million)
Figure 14.172 Other Neurostimulation Devices Market for Overactive Bladder in Australia, 2018-2030 (USD Million)
Figure 14.173 Other Neurostimulation Devices Market for Overactive Bladder in China, 2018-2030 (USD Million)
Figure 14.174 Other Neurostimulation Devices Market for Overactive Bladder in Japan, 2018-2030 (USD Million)
Figure 14.175 Global Other Neurostimulation Devices Market for Heart Failure, 2018-2030 (USD Million)
Figure 14.176 Other Neurostimulation Devices Market for Heart Failure in the US, 2018-2030 (USD Million)
Figure 14.177 Other Neurostimulation Devices Market for Heart Failure in Canada, 2018-2030 (USD Million)
Figure 14.178 Other Neurostimulation Devices Market for Heart Failure in the UK, 2018-2030 (USD Million)
Figure 14.179 Other Neurostimulation Devices Market for Heart Failure in Germany, 2018-2030 (USD Million)
Figure 14.180 Other Neurostimulation Devices Market for Heart Failure in France, 2018-2030 (USD Million)
Figure 14.181 Other Neurostimulation Devices Market for Heart Failure in Spain, 2018-2030 (USD Million)
Figure 14.182 Other Neurostimulation Devices Market for Heart Failure in Italy, 2018-2030 (USD Million)
Figure 14.183 Other Neurostimulation Devices Market for Heart Failure in Australia, 2018-2030 (USD Million)
Figure 14.184 Other Neurostimulation Devices Market for Heart Failure in China, 2018-2030 (USD Million)
Figure 14.185 Other Neurostimulation Devices Market for Heart Failure in Japan, 2018-2030 (USD Million)
Figure 14.186 Global Other Neurostimulation Devices Market for Sleep Apnea, 2018-2030 (USD Million)
Figure 14.187 Other Neurostimulation Devices Market for Sleep Apnea in the US, 2018-2030 (USD Million)
Figure 14.188 Other Neurostimulation Devices Market for Sleep Apnea in Canada, 2018-2030 (USD Million)
Figure 14.189 Other Neurostimulation Devices Market for Sleep Apnea in the UK, 2018-2030 (USD Million)
Figure 14.190 Other Neurostimulation Devices Market for Sleep Apnea in Germany, 2018-2030 (USD Million)
Figure 14.191 Other Neurostimulation Devices Market for Sleep Apnea in France, 2018-2030 (USD Million)
Figure 14.192 Other Neurostimulation Devices Market for Sleep Apnea in Spain, 2018-2030 (USD Million)
Figure 14.193 Other Neurostimulation Devices Market for Sleep Apnea in Italy, 2018-2030 (USD Million)
Figure 14.194 Other Neurostimulation Devices Market for Sleep Apnea in Australia, 2018-2030 (USD Million)
Figure 14.195 Other Neurostimulation Devices Market for Sleep Apnea in China, 2018-2030 (USD Million)
Figure 14.196 Other Neurostimulation Devices Market for Sleep Apnea in Japan, 2018-2030 (USD Million)
Figure 14.197 Global Other Neurostimulation Devices Market, 2018-2030 (Units, Volume)
Figure 14.198 Global Other Neurostimulation Devices Market for Overactive Bladder, 2018-2030 (Units, Volume)
Figure 14.199 Other Neurostimulation Devices Market for Overactive Bladder in the US, 2018-2030 (Units, Volume)
Figure 14.200 Other Neurostimulation Devices Market for Overactive Bladder in Canada, 2018-2030 (Units, Volume)
Figure 14.201 Other Neurostimulation Devices Market for Overactive Bladder in the UK, 2018-2030 (Units, Volume)
Figure 14.202 Other Neurostimulation Devices Market for Overactive Bladder in Germany, 2018-2030 (Units, Volume)
Figure 14.203 Other Neurostimulation Devices Market for Overactive Bladder in France, 2018-2030 (Units, Volume)
Figure 14.204 Other Neurostimulation Devices Market for Overactive Bladder in Spain, 2018-2030 (Units, Volume)
Figure 14.205 Other Neurostimulation Devices Market for Overactive Bladder in Italy, 2018-2030 (Units, Volume)
Figure 14.206 Other Neurostimulation Devices Market for Overactive Bladder in Australia, 2018-2030 (Units, Volume)
Figure 14.207 Other Neurostimulation Devices Market for Overactive Bladder in China, 2018-2030 (Units, Volume)
Figure 14.208 Other Neurostimulation Devices Market for Overactive Bladder in Japan, 2018-2030 (Units, Volume)
Figure 14.209 Global Other Neurostimulation Devices Market for Heart Failure, 2018-2030 (Units, Volume)
Figure 14.210 Other Neurostimulation Devices Market for Heart Failure in the US, 2018-2030 (Units, Volume)
Figure 14.211 Other Neurostimulation Devices Market for Heart Failure in Canada, 2018-2030 (Units, Volume)
Figure 14.212 Other Neurostimulation Devices Market for Heart Failure in the UK, 2018-2030 (Units, Volume)
Figure 14.213 Other Neurostimulation Devices Market for Heart Failure in Germany, 2018-2030 (Units, Volume)
Figure 14.214 Other Neurostimulation Devices Market for Heart Failure in France, 2018-2030 (Units, Volume)
Figure 14.215 Other Neurostimulation Devices Market for Heart Failure in Spain, 2018-2030 (Units, Volume)
Figure 14.216 Other Neurostimulation Devices Market for Heart Failure in Italy, 2018-2030 (Units, Volume)
Figure 14.217 Other Neurostimulation Devices Market for Heart Failure in Australia, 2018-2030 (Units, Volume)
Figure 14.218 Other Neurostimulation Devices Market for Heart Failure in China, 2018-2030 (Units, Volume)
Figure 14.219 Other Neurostimulation Devices Market for Heart Failure in Japan, 2018-2030 (Units, Volume)
Figure 14.220 Global Other Neurostimulation Devices Market for Sleep Apnea, 2018-2030 (Units, Volume)
Figure 14.221 Other Neurostimulation Devices Market for Sleep Apnea in the US, 2018-2030 (Units, Volume)
Figure 14.222 Other Neurostimulation Devices Market for Sleep Apnea in Canada, 2018-2030 (Units, Volume)
Figure 14.223 Other Neurostimulation Devices Market for Sleep Apnea in the UK, 2018-2030 (Units, Volume)
Figure 14.224 Other Neurostimulation Devices Market for Sleep Apnea in Germany, 2018-2030 (Units, Volume)
Figure 14.225 Other Neurostimulation Devices Market for Sleep Apnea in France, 2018-2030 (Units, Volume)
Figure 14.226 Other Neurostimulation Devices Market for Sleep Apnea in Spain, 2018-2030 (Units, Volume)
Figure 14.227 Other Neurostimulation Devices Market for Sleep Apnea in Italy, 2018-2030 (Units, Volume)
Figure 14.228 Other Neurostimulation Devices Market for Sleep Apnea in Australia, 2018-2030 (Units, Volume)
Figure 14.229 Other Neurostimulation Devices Market for Sleep Apnea in China, 2018-2030 (Units, Volume)
Figure 14.230 Other Neurostimulation Devices Market for Sleep Apnea in Japan, 2018-2030 (Units, Volume)
Figure 14.231 Global MRI Compatible Neurostimulation Devices Market, 2018-2030 (USD Million)
Figure 14.232 Global MRI Compatible Neurostimulation Devices Market, 2018-2030 (Units, Volume)
Figure 14.233 Global MRI Non-Compatible Neurostimulation Devices Market, 2018-2030 (USD Million)
Figure 14.234 Global MRI Non-Compatible Neurostimulation Devices Market, 2018-2030 (Units, Volume)
LIST OF TABLES
Table 3.1 Basic Components of Neurostimulation Devices
Table 3.2 Comparison of Different Types of Neurostimulation Devices
Table 4.1 General Guidelines for Market Authorization and Reimbursement for Medical Devices
Table 4.2 Device Classification: US
Table 4.3 Device Classification: Canada
Table 4.4 Data Requirements and Characteristics of Province-wise HTA Processes in Canada
Table 4.5 Regulatory Bodies in EU5 Countries
Table 4.6 Device Classification: Europe
Table 4.7 List of CE Directives in Europe
Table 4.8 Conformity Assessment Modules in Europe
Table 4.9 Device Classification: Australia
Table 4.10 Reimbursement and Pricing Approval Process of Medical Devices in Australia
Table 4.11 Device Classification: China
Table 4.12 Device Classification: Europe
Table 4.13 Medical Device Reimbursement Categories
Table 4.14 Medical Devices: Regulatory and Reimbursement Landscape Summary
Table 5.1 List of Neurostimulation Devices
Table 5.2 List of Neurostimulation Devices: Information on Therapeutic Areas and Development / Approval Status
Table 5.3 Neurostimulation Devices, Heat Map: Distribution by Target Therapeutic Area and Type of Device
Table 5.4 List of Neurostimulation Devices: Information on Key Device Specifications
Table 5.5 List of Additional Neurostimulation Devices
Table 6.1 SCS Devices Competitiveness Analysis: Final Output
Table 6.2 Medtronic: Key Highlights
Table 6.3 Medtronic: Key Characteristics of Intellis™
Table 6.4 Medtronic: Recent Developments and Future Outlook
Table 6.5 Boston Scientific: Key Highlights
Table 6.6 Boston Scientific: Key Characteristics of Precision™ Plus
Table 6.7 Boston Scientific: Recent Developments and Future Outlook
Table 6.8 Stimwave: Key Highlights
Table 6.9 Stimwave: Key Characteristics of Senza®
Table 6.10 Stimwave: Recent Developments and Future Outlook
Table 6.11 Nevro: Key Highlights
Table 6.12 Nevro: Key Characteristics of Senza®
Table 6.13 Nevro: Recent Developments and Future Outlook
Table 7.1 DBS Devices Competitiveness Analysis: Final Output
Table 7.2 Medtronic: Key Characteristics of Activa™ PC, Activa™ SC, Activa™ RC
Table 7.3 Medtronic: Recent Developments and Future Outlook
Table 7.4 Boston Scientific: Key Characteristics of Vercise™ DBS, Vercise Gevia™
Table 7.5 Boston Scientific: Recent Developments and Future Outlook
Table 7.6 Beijing PINS Medical: Key Highlights
Table 7.7 Beijing PINS Medical: Key Characteristics of PINS™ DBS System
Table 7.8 Beijing PINS Medical: Recent Developments and Future Outlook
Table 7.9 Abbott (St. Jude Medical): Key Highlights
Table 7.10 Abbott (St. Jude Medical): Key Characteristics of Brio™
Table 7.11 Abbott (St. Jude Medical): Recent Developments and Future Outlook
Table 8.1 SNS Devices Competitiveness Analysis: Final Output
Table 8.2 Axonics Modulation Technologies: Key Highlights
Table 8.3 Axonics Modulation Technologies: Key Characteristics of Axonics® r-SNM™ System
Table 8.4 Axonics Modulation Technologies: Recent Developments and Future Outlook
Table 8.5 BrainsGate: Key Highlights
Table 8.6 BrainsGate: Key Characteristics of Ischemic Stroke System™
Table 8.7 BrainsGate: Recent Developments and Future Outlook
Table 8.8 Medtronic: Key Characteristics of InterStim II
Table 8.9 VNS Devices Competitiveness Analysis: Final Output
Table 8.10 LivaNova: Key Highlights
Table 8.11 LivaNova: Key Characteristics of Pulse, Pulse Duo, AspireHC®, AspireSR®, SenTiva®
Table 8.12 LivaNova: Recent Developments and Future Outlook
Table 8.13 SetPoint Medical: Key Highlights
Table 8.14 SetPoint Medical: Key Characteristics of Unnamed Bioelectronic Platform
Table 8.15 Setpoint Medical: Recent Developments and Future Outlook
Table 8.16 Synergia Medical: Key Highlights
Table 8.17 Synergia Medical: Key Characteristics of NAOS Platform
Table 8.18 Synergia Medical: Recent Developments and Future Outlook
Table 8.19 Other CNS Devices Competitiveness Analysis: Final Output
Table 8.20 Bioness: Key Highlights
Table 8.21 Bioness: Key Characteristics of StimRouter®
Table 8.22 Bioness: Recent Developments and Future Outlook
Table 8.23 Nyxoah: Key Highlights
Table 8.24 Nyxoah: Funding Instances
Table 8.25 Nyxoah: Key Characteristics of Genio™
Table 8.26 Nyxoah: Recent Developments and Future Outlook
Table 8.27 BlueWind Medical: Key Highlights
Table 8.28 BlueWind Medical: Key Characteristics of RENOVA™, VIVENDI™
Table 8.29 BlueWind Medical: Recent Developments and Future Outlook
Table 10.1 Patents: CPC Classification Symbol Definitions
Table 10.2 Patents: Most Popular CPC Classification Symbols
Table 10.3 Patents: List of Top CPC Classifications
Table 10.4 Patents: List of Leading Individual Assignees
Table 10.5 Patents: Summary of Benchmarking Analysis
Table 10.6 Patent Valuation Analysis: Categorization based on Weighted Scores
Table 10.7 Patents: List of Leading Patents (by Highest Relative Valuation)
Table 10.8 Patents: List of Leading Patents (by Number of Citations)
Table 12.1 Neurostimulation Devices: List of Partnerships
Table 12.2 Recent Partnerships: Most Active Players
Table 13.1 Neurostimulation Devices: Funding and Investments, January 2015-June 2018
Table 13.2 Neurostimulation Devices: Summary of Investments
Table 16.1 NeuroOne Medical Technologies: Key Highlights
Table 16.2 ReShape Lifesciences: Key Highlights
Table 16.3 Mainstay Medical: Key Highlights
Table 16.4 Stimwave: Key Highlights
Table 16.5 WISE: Key Highlights
Table 16.6 Cardionomic: Key Highlights
Table 17.1 List of Non-invasive Neurostimulation Devices
Table 18.1 DALYs and Deaths from Selected Neurological Disorders, 2015
Table 18.2 Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
Table 18.3 Healthcare Insurance Coverage in Canada: Distribution by Type of Coverage
Table 18.4 Healthcare Insurance Coverage in the UK: Distribution by Type of Coverage
Table 18.5 Healthcare Insurance Coverage in Germany: Distribution by Type of Coverage
Table 18.6 Healthcare Insurance Coverage in France: Distribution by Type of Coverage
Table 18.7 Healthcare Insurance Coverage in Spain: Distribution by Type of Coverage
Table 18.8 Healthcare Insurance Coverage in Italy: Distribution by Type of Coverage
Table 18.9 Healthcare Insurance Coverage in Australia: Distribution by Type of Coverage
Table 18.10 Healthcare Insurance Coverage in China: Distribution by Type of Coverage
Table 18.11 Healthcare Insurance Coverage in Japan: Distribution by Type of Coverage
Table 18.12 Neurostimulation Devices: Distribution of Industry Players by Year of Establishment
Table 18.13 Neurostimulation Devices: Distribution of Industry Players by Geographical Location
Table 18.14 Neurostimulation Devices: Distribution of Industry Players by Size (Employee Count)
Table 18.15 Neurostimulation Devices: Leading Developers in Terms of Number of Devices
Table 18.16 Neurostimulation Devices: Distribution by Types of Devices
Table 18.17 Neurostimulation Devices: Distribution by Types of Target Nerves
Table 18.18 Neurostimulation Devices: Leading Target Indications in Terms of Number of Devices
Table 18.19 Neurostimulation Devices: Distribution by Types of Regulatory Approvals
Table 18.20 Neurostimulation Devices: Distribution by Size
Table 18.21 Neurostimulation Devices: Distribution by Weight
Table 18.22 Neurostimulation Devices: Distribution by Battery Type
Table 18.23 Neurostimulation Devices: Distribution by Battery Longevity
Table 18.24 Neurostimulation Devices: Distribution by Number of Electrodes
Table 18.25 Neurostimulation Devices: Distribution by MRI Compatibility
Table 18.26 Medtronic: Revenues, FY 2014-FY 2018 (USD Billion)
Table 18.27 Medtronic, Revenues: Distribution by Business Segments, FY 2018 (USD Billion)
Table 18.28 Medtronic, Revenues: Distribution by Regions, FY 2018 (USD Billion)
Table 18.29 Boston Scientific: Revenues, FY 2013-H1 FY 2018 (USD Billion)
Table 18.30 Boston Scientific, Revenues: Distribution by Business Segments, FY 2017 (USD Billion)
Table 18.31 Boston Scientific, Revenues: Distribution by Regions, FY 2017 (USD Billion)
Table 18.32 Nevro: Revenues, FY 2013-Q1 FY 2018 (USD Million)
Table 18.33 Nevro, Revenues: Distribution by Regions, FY 2017 (USD Million)
Table 18.34 Abbott: Revenues, FY 2013-H1 FY 2018 (USD Billion)
Table 18.35 Abbott, Revenues: Distribution by Business Segments, FY 2017 (USD Billion)
Table 18.36 Abbott, Revenues: Distribution by Regions, FY 2017 (USD Billion)
Table 18.37 LivaNova: Revenues, FY 2015-Q1 FY 2018 (USD Million)
Table 18.38 LivaNova, Revenues: Distribution by Business Segments, FY 2017 (USD Million)
Table 18.39 LivaNova, Revenues: Distribution by Regions, FY 2017 (USD Million)
Table 18.40 Patents: Distribution by Type
Table 18.41 Patents: Cumulative Trend by Publication Year
Table 18.42 Patents: Distribution by Geographical Location
Table 18.43 Patents: Distribution by Leading Players
Table 18.44 Boston Scientific and Medtronic: Benchmarking by Patent Characteristics
Table 18.45 Other Leading Patent Assignees: Benchmarking by Patent Characteristics
Table 18.46 Industry Players: Benchmarking by Number of Patents Published Across Different Geographies
Table 18.47 Industry Players: Benchmarking by Number of International Patents
Table 18.48 Patents: Distribution by Age (January 2010-June 2018)
Table 18.49 Patent Valuation
Table 18.50 Clinical Trials: Distribution by Trial Status
Table 18.51 Clinical Trials: Distribution by Registration Year
Table 18.52 Clinical Trials: Geographical Distribution by Number of Trials
Table 18.53 Clinical Trials: Geographical Distribution by Enrolled Patient Population
Table 18.54 Clinical Trials: Year-wise Trend of Trial Recruitment Status
Table 18.55 Clinical Trials: Geographical Distribution by Registration Year and Recruitment Status
Table 18.56 Clinical Trials: Distribution by Type of Sponsors / Collaborators
Table 18.57 Clinical Trials: Most Active Industry Players in Terms of Number of Trials Conducted
Table 18.58 Clinical Trials: Most Active Non-Industry Players in Terms of Number of Trials Conducted
Table 18.59 Clinical Trials: Leading Indications in Terms of Number of Trials
Table 18.60 Clinical Trials: Year-wise Trend of Top Five Indications
Table 18.61 Recent Partnerships: Cumulative Half Year-wise Trend (2015–H1 2018)
Table 18.62 Recent Partnerships: Distribution by Type of Model
Table 18.63 Recent Partnerships: Distribution by Year of Partnership and Type of Model
Table 18.64 Recent Partnerships: Distribution by Type of Device
Table 18.65 Recent Partnerships: Distribution by Year of Partnership and Type of Device
Table 18.66 Recent Partnerships: Most Active Players
Table 18.67 Recent Partnerships: Regional Distribution and Most Active Players
Table 18.68 Recent Partnerships: Regional Distribution by Intercontinental and Intracontinental Agreements
Table 18.69 Funding Instances: Cumulative Half Year-wise trend, January 2015-June 2018
Table 18.70 Funding Instances: Cumulative Amount Invested, January 2015-June 2018 (USD Million)
Table 18.71 Funding Instances: Distribution by Type of Funding, January 2015-June 2018
Table 18.72 Funding Instances: Distribution by Amount Invested and Type of Funding, January 2015-June 2018 (USD Million)
Table 18.73 Summary of Investments, January 2015-June 2018 (USD Million)
Table 18.74 Funding Instances: Most Popular Device Types by Number of Instances, January 2015-June 2018
Table 18.75 Funding Instances: Most Popular Device Types by Amount Invested, January 2015-June 2018 (USD Million)
Table 18.76 Funding Instances: Distribution by Year of Investment and Type of Device, January 2015-June 2018 (USD Million)
Table 18.77 Funding Instances: Most Active Players in Terms of Number of Instances, January 2015-June 2018
Table 18.78 Funding Instances: Most Active Players in Terms of Amount Invested, January 2015-June 2018
Table 18.79 Funding Instances: Most Active Investors in Terms of Number of Instances, January 2015-June 2018
Table 18.80 Funding Instances: Funding and Investment Summary
Table 18.81 Global Neurostimulation Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.82 Global Neurostimulation Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.83 Global SCS Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.84 Global SCS Devices Market for Chronic Pain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.85 SCS Devices Market for Chronic Pain in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.86 SCS Devices Market for Chronic Pain in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.87 SCS Devices Market for Chronic Pain in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.88 SCS Devices Market for Chronic Pain in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.89 SCS Devices Market for Chronic Pain in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.90 SCS Devices Market for Chronic Pain in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.91 SCS Devices Market for Chronic Pain in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.92 SCS Devices Market for Chronic Pain in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.93 SCS Devices Market for Chronic Pain in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.94 SCS Devices Market for Chronic Pain in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.95 Global SCS Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.96 Global SCS Devices Market for Chronic Pain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.97 SCS Devices Market for Chronic Pain in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.98 SCS Devices Market for Chronic Pain in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.99 SCS Devices Market for Chronic Pain in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.100 SCS Devices Market for Chronic Pain in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.101 SCS Devices Market for Chronic Pain in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.102 SCS Devices Market for Chronic Pain in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.103 SCS Devices Market for Chronic Pain in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.104 SCS Devices Market for Chronic Pain in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.105 SCS Devices Market for Chronic Pain in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.107 SCS Devices Market for Chronic Pain in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.108 Global DBS Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.109 Global DBS Devices Market for Essential Tremor, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.110 DBS Devices Market for Essential Tremor in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.111 DBS Devices Market for Essential Tremor in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.112 DBS Devices Market for Essential Tremor in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.113 DBS Devices Market for Essential Tremor in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.114 DBS Devices Market for Essential Tremor in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.115 DBS Devices Market for Essential Tremor in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.116 DBS Devices Market for Essential Tremor in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.117 DBS Devices Market for Essential Tremor in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.118 DBS Devices Market for Essential Tremor in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.119 DBS Devices Market for Essential Tremor in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.120 Global DBS Devices Market for Parkinson’s Disease, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.121 DBS Devices Market for Parkinson’s Disease in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.122 DBS Devices Market for Parkinson’s Disease in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.123 DBS Devices Market for Parkinson’s Disease in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.124 DBS Devices Market for Parkinson’s Disease in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.125 DBS Devices Market for Parkinson’s Disease in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.126 DBS Devices Market for Parkinson’s Disease in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.127 DBS Devices Market for Parkinson’s Disease in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.128 DBS Devices Market for Parkinson’s Disease in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.129 DBS Devices Market for Parkinson’s Disease in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.130 DBS Devices Market for Parkinson’s Disease in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.131 Global DBS Devices Market for Dystonia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.132 DBS Devices Market for Dystonia in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.133 DBS Devices Market for Dystonia in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.134 DBS Devices Market for Dystonia in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.135 DBS Devices Market for Dystonia in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.136 DBS Devices Market for Dystonia in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.137 DBS Devices Market for Dystonia in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.138 DBS Devices Market for Dystonia in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.139 DBS Devices Market for Dystonia in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.140 DBS Devices Market for Dystonia in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.141 DBS Devices Market for Dystonia in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.142 Global DBS Devices Market for Obsessive Compulsive Disorder, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.143 DBS Devices Market for Obsessive Compulsive Disorder in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.144 DBS Devices Market for Obsessive Compulsive Disorder in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.145 DBS Devices Market for Obsessive Compulsive Disorder in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.146 DBS Devices Market for Obsessive Compulsive Disorder in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.147 DBS Devices Market for Obsessive Compulsive Disorder in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.148 DBS Devices Market for Obsessive Compulsive Disorder in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.149 DBS Devices Market for Obsessive Compulsive Disorder in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.150 DBS Devices Market for Obsessive Compulsive Disorder in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.151 DBS Devices Market for Obsessive Compulsive Disorder in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.152 DBS Devices Market for Obsessive Compulsive Disorder in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.153 Global DBS Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.154 Global DBS Devices Market for Essential Tremor, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.155 DBS Devices Market for Essential Tremor in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.156 DBS Devices Market for Essential Tremor in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.157 DBS Devices Market for Essential Tremor in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.158 DBS Devices Market for Essential Tremor in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.159 DBS Devices Market for Essential Tremor in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.160 DBS Devices Market for Essential Tremor in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.161 DBS Devices Market for Essential Tremor in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.162 DBS Devices Market for Essential Tremor in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.163 DBS Devices Market for Essential Tremor in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.164 DBS Devices Market for Essential Tremor in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.165 Global DBS Devices Market for Parkinson’s Disease, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.166 DBS Devices Market for Parkinson’s Disease in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.167 DBS Devices Market for Parkinson’s Disease in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.168 DBS Devices Market for Parkinson’s Disease in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.169 DBS Devices Market for Parkinson’s Disease in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.170 DBS Devices Market for Parkinson’s Disease in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.171 DBS Devices Market for Parkinson’s Disease in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.172 DBS Devices Market for Parkinson’s Disease in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.173 DBS Devices Market for Parkinson’s Disease in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.174 DBS Devices Market for Parkinson’s Disease in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.175 DBS Devices Market for Parkinson’s Disease in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.176 Global DBS Devices Market for Dystonia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.177 DBS Devices Market for Dystonia in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.178 DBS Devices Market for Dystonia in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.179 DBS Devices Market for Dystonia in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.180 DBS Devices Market for Dystonia in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.181 DBS Devices Market for Dystonia in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.182 DBS Devices Market for Dystonia in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.183 DBS Devices Market for Dystonia in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.184 DBS Devices Market for Dystonia in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.185 DBS Devices Market for Dystonia in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.186 DBS Devices Market for Dystonia in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.187 Global DBS Devices Market for Obsessive Compulsive Disorder, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.188 DBS Devices Market for Obsessive Compulsive Disorder in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.189 DBS Devices Market for Obsessive Compulsive Disorder in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.190 DBS Devices Market for Obsessive Compulsive Disorder in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.191 DBS Devices Market for Obsessive Compulsive Disorder in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.192 DBS Devices Market for Obsessive Compulsive Disorder in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.193 DBS Devices Market for Obsessive Compulsive Disorder in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.194 DBS Devices Market for Obsessive Compulsive Disorder in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.195 DBS Devices Market for Obsessive Compulsive Disorder in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.196 DBS Devices Market for Obsessive Compulsive Disorder in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.197 DBS Devices Market for Obsessive Compulsive Disorder in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.198 Global VNS Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.199 Global VNS Devices Market for Epilepsy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.200 VNS Devices Market for Epilepsy in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.201 VNS Devices Market for Epilepsy in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.202 VNS Devices Market for Epilepsy in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.203 VNS Devices Market for Epilepsy in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.204 VNS Devices Market for Epilepsy in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.205 VNS Devices Market for Epilepsy in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.206 VNS Devices Market for Epilepsy in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.207 VNS Devices Market for Epilepsy in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.208 VNS Devices Market for Epilepsy in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.209 VNS Devices Market for Epilepsy in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.210 Global VNS Devices Market for Major Depressive Disorder, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.211 VNS Devices Market for Major Depressive Disorder in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.212 VNS Devices Market for Major Depressive Disorder in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.213 VNS Devices Market for Major Depressive Disorder in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.214 VNS Devices Market for Major Depressive Disorder in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.215 VNS Devices Market for Major Depressive Disorder in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.216 VNS Devices Market for Major Depressive Disorder in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.217 VNS Devices Market for Major Depressive Disorder in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.218 VNS Devices Market for Major Depressive Disorder in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.219 VNS Devices Market for Major Depressive Disorder in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.220 VNS Devices Market for Major Depressive Disorder in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.221 Global VNS Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.222 Global VNS Devices Market for Epilepsy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.223 VNS Devices Market for Epilepsy in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.224 VNS Devices Market for Epilepsy in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.225 VNS Devices Market for Epilepsy in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.226 VNS Devices Market for Epilepsy in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.227 VNS Devices Market for Epilepsy in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.228 VNS Devices Market for Epilepsy in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.229 VNS Devices Market for Epilepsy in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.230 VNS Devices Market for Epilepsy in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.231 VNS Devices Market for Epilepsy in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.232 VNS Devices Market for Epilepsy in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.233 Global VNS Devices Market for Major Depressive Disorder, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.234 VNS Devices Market for Major Depressive Disorder in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.235 VNS Devices Market for Major Depressive Disorder in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.236 VNS Devices Market for Major Depressive Disorder in the UK, Conservative, Base an8d Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.237 VNS Devices Market for Major Depressive Disorder in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.238 VNS Devices Market for Major Depressive Disorder in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.239 VNS Devices Market for Major Depressive Disorder in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.240 VNS Devices Market for Major Depressive Disorder in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.241 VNS Devices Market for Major Depressive Disorder in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.242 VNS Devices Market for Major Depressive Disorder in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.243 VNS Devices Market for Major Depressive Disorder in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.244 Global Other Neurostimulation Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.245 Global Other Neurostimulation Devices Market for Overactive Bladder, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.246 Other Neurostimulation Devices Market for Overactive Bladder in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.247 Other Neurostimulation Devices Market for Overactive Bladder in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.248 Other Neurostimulation Devices Market for Overactive Bladder in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.249 Other Neurostimulation Devices Market for Overactive Bladder in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.250 Other Neurostimulation Devices Market for Overactive Bladder in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.251 Other Neurostimulation Devices Market for Overactive Bladder in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.252 Other Neurostimulation Devices Market for Overactive Bladder in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.253 Other Neurostimulation Devices Market for Overactive Bladder in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.254 Other Neurostimulation Devices Market for Overactive Bladder in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.255 Other Neurostimulation Devices Market for Overactive Bladder in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.256 Global Other Neurostimulation Devices Market for Heart Failure, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.257 Other Neurostimulation Devices Market for Heart Failure in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.258 Other Neurostimulation Devices Market for Heart Failure in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.259 Other Neurostimulation Devices Market for Heart Failure in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.260 Other Neurostimulation Devices Market for Heart Failure in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.261 Other Neurostimulation Devices Market for Heart Failure in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.262 Other Neurostimulation Devices Market for Heart Failure in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.263 Other Neurostimulation Devices Market for Heart Failure in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.264 Other Neurostimulation Devices Market for Heart Failure in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.265 Other Neurostimulation Devices Market for Heart Failure in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.266 Other Neurostimulation Devices Market for Heart Failure in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.267 Global Other Neurostimulation Devices Market for Sleep Apnea, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.268 Other Neurostimulation Devices Market for Sleep Apnea in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.269 Other Neurostimulation Devices Market for Sleep Apnea in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.270 Other Neurostimulation Devices Market for Sleep Apnea in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.271 Other Neurostimulation Devices Market for Sleep Apnea in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.272 Other Neurostimulation Devices Market for Sleep Apnea in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.273 Other Neurostimulation Devices Market for Sleep Apnea in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.274 Other Neurostimulation Devices Market for Sleep Apnea in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.275 Other Neurostimulation Devices Market for Sleep Apnea in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.276 Other Neurostimulation Devices Market for Sleep Apnea in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.277 Other Neurostimulation Devices Market for Sleep Apnea in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.278 Global Other Neurostimulation Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.279 Global Other Neurostimulation Devices Market for Overactive Bladder, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.280 Other Neurostimulation Devices Market for Overactive Bladder in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.281 Other Neurostimulation Devices Market for Overactive Bladder in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.282 Other Neurostimulation Devices Market for Overactive Bladder in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.283 Other Neurostimulation Devices Market for Overactive Bladder in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.284 Other Neurostimulation Devices Market for Overactive Bladder in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.285 Other Neurostimulation Devices Market for Overactive Bladder in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.286 Other Neurostimulation Devices Market for Overactive Bladder in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.287 Other Neurostimulation Devices Market for Overactive Bladder in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.288 Other Neurostimulation Devices Market for Overactive Bladder in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.289 Other Neurostimulation Devices Market for Overactive Bladder in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.290 Global Other Neurostimulation Devices Market for Heart Failure, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.291 Other Neurostimulation Devices Market for Heart Failure in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.292 Other Neurostimulation Devices Market for Heart Failure in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.293 Other Neurostimulation Devices Market for Heart Failure in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.294 Other Neurostimulation Devices Market for Heart Failure in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.295 Other Neurostimulation Devices Market for Heart Failure in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.296 Other Neurostimulation Devices Market for Heart Failure in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.297 Other Neurostimulation Devices Market for Heart Failure in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.298 Other Neurostimulation Devices Market for Heart Failure in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.299 Other Neurostimulation Devices Market for Heart Failure in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.300 Other Neurostimulation Devices Market for Heart Failure in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.301 Global Other Neurostimulation Devices Market for Sleep Apnea, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.302 Other Neurostimulation Devices Market for Sleep Apnea in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.303 Other Neurostimulation Devices Market for Sleep Apnea in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.304 Other Neurostimulation Devices Market for Sleep Apnea in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.305 Other Neurostimulation Devices Market for Sleep Apnea in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.306 Other Neurostimulation Devices Market for Sleep Apnea in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.307 Other Neurostimulation Devices Market for Sleep Apnea in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.308 Other Neurostimulation Devices Market for Sleep Apnea in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.309 Other Neurostimulation Devices Market for Sleep Apnea in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.310 Other Neurostimulation Devices Market for Sleep Apnea in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.311 Other Neurostimulation Devices Market for Sleep Apnea in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.312 Global MRI Compatible Neurostimulation Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.313 Global MRI Compatible Neurostimulation Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.314 Global MRI Non-Compatible Neurostimulation Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.315 Global MRI Non-Compatible Neurostimulation Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook